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Abstract 
 
Background: Clinical retention is central to the HIV care continuum and a determinant 
of improved individual- and population-level HIV outcomes. The goals of this 
dissertation are to improve retention surveillance by quantifying measurement error due 
to laboratory-measure proxies for encounters and to examine retention disparities by 
demographic, HIV risk, and geographic characteristics, using data from 2000-2010. 
Methods: We analyzed data from the North American AIDS Cohort Collaboration on 
Research and Design, the largest North American HIV cohort collaboration. Clinical 
retention was defined using the Institute of Medicine indicator: ≥2 encounters, >90 days 
apart, within one calendar year. Discordance between laboratory-based and encounter-
based retention measures was evaluated using logistic regression with GEE and inverse 
probability weights for confounder adjustment.  Relative times and cumulative incidences 
of first retention discontinuation after ART initiation by demographic and HIV risk 
factors were analyzed using weighted Cox regression.  Geographic differences were 
assessed using modified Poisson and logistic regression with GEE and cluster detection 
methods. 
Results: We identified significant retention disparities by measurement method, patient 
characteristics, and geography, even adjusting for confounders and clinical practice 
differences. Misclassification of encounter-based retention by laboratory-based measures 
was 19% overall, which remained stable over time.  Among individuals initiating ART, 
the cumulative incidence of retention discontinuation was 74% and adjusted cause-
specific hazard ratios (HR) were lower for females (HR: 0.81, vs. males), but higher for 
Black (HR: 1.18, vs. non-Black) patients and individuals with injection drug use as HIV 
	   iii 
risk (IDU) (HR: 1.35, vs. non-IDU) (p<0.05, each). The South and West (adjusted Risk 
Ratios [RR]: 0.95 and 0.89, respectively) lagged the Northeast and Midwest (Ref. and 
RR: 1.03) in improved retention over the study period (p<0.05, each).  
Conclusions: Clinical retention improved within all groups over time, yet disparities by 
important characteristics persisted. Agreement between encounter-based and laboratory-
based metrics was strong, but laboratory measures were imperfect proxies.  Public health 
interventions to address poor retention in high-risk populations are needed, and more 
accurate surveillance of care outcomes will be essential in monitoring HIV policy 
benchmarks if, indeed, we are to continue to make progress toward them.  
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Overview and specific aims 
 
Retention in clinical HIV care has been widely recognized as a key component in 
improving HIV disease outcomes in individuals and decreasing HIV transmission in 
populations. Measures of retention in clinical care have varied depending on the available 
data and the population under study, and various demographic, clinical, and 
environmental characteristics have been observed influencing patterns of care over time.  
Recently, the National HIV/AIDS Strategy (NHAS) for the United States advocated 
improvement in clinical retention rates and the Institute of Medicine (IOM) outlined 
measures for assessing both the NHAS and benchmarks in the Affordable Care Act.  
This dissertation therefore seeks to quantify clinical, sociodemographic, and 
geographic patterns and correlates of retention in care among HIV-infected persons in the 
United States (US) and Canada, with a particular focus on individuals historically 
deemed to be at greater risk of suboptimal care and HIV outcomes, such as younger, male 
patients, minorities, and those with a history of injection drug use (IDU). The North 
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) provides 
a rich data source that has been endorsed by the IOM as an important resource capable of 
monitoring patterns of care among persons living with HIV/AIDS (PLWHA) in the 
United States and assessing progress in the NHAS. The results of these analyses will 
provide evidence to clinic-directors and state and federal policy makers regarding 
effective strategies to measure and improve clinical retention, in line with 
recommendations for measures of quality HIV care by the IOM and retention targets in 
the US National HIV/AIDS Strategy.(1-3) 
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Aim 1 addresses the concordance of laboratory measures (used as surrogates for 
direct measures of clinical encounters) with actual clinical encounters between 2000 and 
2010.  Because laboratory measures are widely used as indicators of access to clinical 
care, this analysis is of significant importance and has not been previously addressed in 
the literature. 
Aim 2 addresses the relationship between demographic and clinical characteristics 
and suboptimal clinical retention after initiation of ART.  The analyses appropriately 
account for differential access to care, potential confounding factors, and the competing 
risk of death, and focus on disparities in clinical retention among HIV-infected 
individuals in North America over the first decade of the 2000s. Mediation by immune 
status will also be modeled over the same time-frame. 
Aim 3 addresses geographic factors associated with suboptimal retention in care 
between 2000 and 2010; regression modeling and spatial statistics are used to compare 
regions and detect clustering of outcomes over space and time.  
 
The specific aims of this dissertation are:   
 
Aim 1: To quantify the agreement between measures of clinical retention defined by 
clinic encounters (attended appointments) versus laboratory measures (acquisition of 
CD4 lymphocyte count or HIV-1 viral load, as surrogates for encounters) among 
individuals with both encounter and laboratory data from 13 NA-ACCORD clinical 
cohorts between 2000 and 2010. 
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Hypotheses: There will be significant positive correlation between measures of 
clinical retention based on encounters and those based on laboratory measures 
among patients in clinical cohorts in the NA-ACCORD between 2000 and 2010.  
Aim 2: To identify disparities in retention by patient characteristics after accounting for 
access to ART and changes in markers of disease progression (CD4 lymphocyte count) 
using appropriate mediation analysis and competing risk methods. Inverse probability of 
selection weighting and cause-specific proportional hazards regression may be used to 
control for the laboratory measures as mediators of other demographic or geographic 
factors associated with healthcare access behavior.  
Hypotheses: Younger, male, and minority individuals will be at heightened risk of 
suboptimal retention even after accounting for deteriorating health (lower CD4 
count) or improving health (higher CD4) over time.  There will also be poorer 
retention outcomes among individuals with a history of IDU, even after initiation 
of ART. 
Aim 3: To characterize geographic variation and clustering of suboptimal clinical 
retention among individuals with geographic information (including state, province, or 3-
digit postal code of residence) available within the NA-ACCORD between 2000 and 
2010; descriptive comparisons and spatial statistics including the Kulldorff spatial scan 
statistic and spatial cluster detection analysis for longitudinal outcomes will be used. 
Hypotheses: Significant differences in retention exist by geographic region and 





Retention in Clinical Care: A core indicator of quality care for HIV-1 infected 
individuals 
 
Of the estimated 1.1 million PLWHA in the US, approximately 80% are aware of their 
infection status(4), and of those, only an estimated 75% are linked to clinical HIV care.(5) 
The retention of those patients linked to clinical care has been described as a critical 
component of improving virologic outcomes and driving down HIV transmission, 
particularly through a “test and treat” strategy.(5) 
Since 2009, the US Health Resources and Services Administration (HRSA) 
HIV/AIDS Bureau (HAB) has defined retention in clinical care for HIV-infected 
individuals as 2 encounters within 12 months, but greater than 90 days apart, excluding 
individuals who entered care in the last half of a calendar year.  These guidelines were 
established in reference to a single calendar period for purposes of annual HRSA HAB 
reporting requirements.(6) In the past several years, others have used multiple measures to 
assess retention and to assess correlated suppression of HIV-1 viral load after 12 months 
in clinical populations, and have found high correlation within measures of visit 
adherence (numbers of missed appointments, proportion of kept appointments, or 
proportion of time under observation meeting the HRSA HAB standard in serial 12-
month periods) and within measures of visit constancy (number of 4- or 6-month 
intervals with at least one kept appointment), but low correlation across these two 
categories of clinical retention measures.(7-9) Recently, following healthcare policy 
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research under the auspices of government and private industry,(6,10) the Institute of 
Medicine of the National Academies endorsed the HRSA HAB measure as one of its core 
indicators of quality HIV clinical care.(3) The National Institutes of Health (NIH) has 
noted:  
One of the limitations in HIV care continuum research to date is 
that most current understanding of patients' success and challenges in 
navigating the care continuum is derived from cross-sectional data. 
However, initiating treatment and engagement in care is not always a 
linear process; a substantial portion of patients are intermittently engaged 
in care. Also, some patients disengage from care for a significant period of 
time, and are thus defined as "lost to care." … Collectively, this set of 
issues suggests a need for studies that examine progress through the 
continuum of care in pathways that are less step-wise. 
Population-based data used to summarize HIV continuum 
outcomes in various catchment areas may also mask important differences 
between subgroups, and these differences may also vary by context. If the 
overall goal is to improve patient outcomes and potentially reduce new 
infections, then it is critical to better understand and intervene with those 
at highest risk for HIV infection … and those most likely to have 
difficulties entering and navigating the continuum of HIV care … 
Therefore, to the extent possible, more fine-grained data, analyses, and 
study are needed regarding subgroups within the treatment cascade, and to 
better identify targets for tailored interventions.  
 
The National Institutes of Drug Abuse (NIDA) has also declared domestic research goals 
of “reducing racial/ethnic disparities in HIV testing, access, and utilization of treatment 
and services” and “…expanding HIV testing, linkage, and retention in care for hard-to-
reach populations” that this research speaks to.(11,12) 
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Though laboratory measures have been widely used as surrogates for care (when 
encounter data is unavailable, as is often the case in larger studies) and shown to be good 
indicators of initial or overall access to clinical HIV care to date, there have been no 
longitudinal studies establishing the actual concordance or correlation between direct 
measures of clinical retention (i.e., those defined by encounters or visits) and those using 
laboratory measures as surrogates among HIV-infected individuals over time.(3,9,13-15)  
Aim 1 seeks to fill a gap in knowledge and provide quantitative evidence to support the 
assertions of concordance between CD4 count or HIV-1 viral load measures and clinical 
encounters, as outlined above. 
 
Significance of clinical retention for improved HIV disease outcomes and review of 
published research  
 
Several studies have established an association between suboptimal clinical retention 
(defined by absences from care, missed visits, or non-compliance with HRSA HAB 
guidelines) and increased likelihood of virologic failure while on antiretroviral therapy 
(ART), increased likelihood of high-risk behavior, and poorer survival.(15-19) The 
implication, echoed in the advocacy of improved retention in both US and Canadian 
national HIV/AIDS strategies, is that retention in clinical care is as important as early 
diagnosis and linkage to care for blunting the progression of HIV and its clinical 
sequelae.(1,5,20-23) 
Disparities in the initial access to and subsequent retention in HIV clinical care 
among PLWHA, according to patient demographic and clinical factors, have been 
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extensively documented.(13,14,16-19,24-31) At least one study has also tied racial disparities in 
HIV virologic outcomes directly to disparities in clinic attendance and retention.(19) Given 
the simultaneous priority placed on the reduction of health disparities and inequities, and 
the relationship between the narrowing of retention disparities and the narrowing of HIV 
disease outcome disparities, there should be a commensurate focus on improving clinical 
retention among PLWHA engaged in care. 
To date, there have been few longitudinal evaluations of individual disparities in 
losses to retention after ART initiation, and in the existent literature, the focus remains on 
complete ascertainment of clinical trial outcomes in the developing world.(32-34) Much of 
the literature addressing racial or sex disparities in retention either does not specifically 
address changes in retention following the initiation of therapy, or adjusts for time on 
therapy as a covariate in regression analyses, a technique that may not account for equity 
in access to care as well as examining individuals’ retention experience from a common 
origin of ART initiation. (27,35,36) Therefore, the disparities noted may be indicative of 
more distal relationships between environment and contextual factors or may be related 
to more proximal and potentially more immediately addressable clinic-level factors. Aim 
2 seeks to capitalize on the longitudinal clinical information available within the NA-
ACCORD in the large variety of clinical settings as they’re currently constituted across 
North America to assess ongoing disparities in retention in the US and Canada, 
controlling for access to care by examining only those individuals initiating therapy. 
Multiple studies have attempted to discern factors associated with suboptimal 
retention in a clinical setting.  Many of these have found race, sex, age, and historical 
injection drug use to be significantly associated with having suboptimal retention (either 
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through larger numbers of discontinuities in care, or larger proportions of time under 
follow-up without clinical care), though studies have differed on whether males or 
females are at greater risk.(8,14,16,19,21,24,25,27,28,31) However, these studies addressed 
suboptimal retention either as an exposure with a clinical outcome (including AIDS-
related illnesses, mortality, and CD4 count and HIV-1 viral load) or as an outcome itself, 
without examining the mediation effects of CD4 count (an indicator of immune health).  
Aim 2 seeks to remedy this gap through the use of the more sophisticated but well-
described epidemiologic method of inverse probability of selection weighting and 
through direct regression adjustment.(37,38) Furthermore, though these studies each 
identified similar factors, there was not considerable geographic heterogeneity in the 
patient population of any single study; studies conducted within Birmingham, AL,(19,24) 
Chapel Hill, NC,(27) San Francisco, CA(28) and New York City, NY(31) cannot be assumed 
to describe larger geographic patterns in clinical care retention among PLWHA across the 
US on their own, and they may suffer from barriers to external generalizability (e.g., 
larger distances between residence and clinical site may be related with lower rates of 
clinical retention for patients outside large urban centers).  Aim 3 seeks to clarify these 
issues by describing and quantifying the geographic heterogeneity of clinical retention 
among PLWHA.  
The consistency of association between the characteristics described above and 
clinical retention, and the association of these same characteristics with poorer HIV 
disease outcomes,(25) underlines the rationale for continued monitoring of clinical 




Study Populations and data sources  
 
The complete evaluation of retention of PLWHA in clinical care would be 
possible in the case of a nationally linked clinical care network or claims database, 
through which the clinic encounter records of all people living within the region and 
accessing clinical HIV care would be available.  One ambitious study, the US Centers For 
Disease Control and Prevention-funded Medical Monitoring Project, was designed to 
monitor clinical care among a nationally representative sample of HIV-infected 
individuals, but it is in reality a serial cross-sectional study similar to the National Health 
and Nutrition Examination Survey (NHANES), and is therefore unsuitable to examine 
longitudinal trends accounting for within-individual correlation of behavior over time.(39) 
We therefore examined factors associated with retention in clinical HIV care and the 
geographic patterns of suboptimal retention across the US using data from the largest 
cohort collaboration including HIV-infected individuals in the US.  The NA-ACCORD, 
the North American member of the NIH-sponsored International epidemiologic 
Databases to Evaluate AIDS (IeDEA) project, is a collaboration which began collecting 
data from multi- and single-site interval and clinical cohorts in 2006.(40) Currently, there 
are 25 included cohorts comprised of patients from 43 of the 50 US states, Washington, 
D.C., Puerto Rico, and 9 of the 13 Canadian provinces; more than 120,000 patients were 
included in the latest data upload.  In the NA-ACCORD patient population, 24% are 
women, 40% are black or African-American, 38% are white, 0.9% are Asian or Pacific 
Islander, 0.7% are American Indian or Alaskan Native, and 0.7% are Multiracial; 15% 
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are of Hispanic ethnicity (of any race), and 5% are of unknown or other race/ethnicity. 
Based on age at study entry, the age distribution among individuals in this population 
was: age 18-24, 4.2%; age 25-34, 22.5%; age 35-44, 41.1%; age 45-54, 24.8%; age 55-
64, 6.2%; age 65+, 1.2%.   
Clinical and demographic data (including multiple laboratory values and 
collection dates, medical diagnoses and dates, antiretroviral medication names and 
prescription dates, clinic encounter information, basic insurance status, and 3-digit zip 
code) are transmitted to a centrally-administered Data Management Core semi-annually 
where all contributed datasets are harmonized. Data undergo quality control for 
completeness and accuracy, including measures to reduce the probability that an 
individual was concurrently participating in more than one clinical cohort. Because both 
historic clinic encounter and laboratory collection data were included in the latest round 
of data uploads (spanning the period 2000 to 2010), a more complete picture of clinical 
HIV care in the US and Canada is now available.   
According to the IOM, the NA-ACCORD has demonstrated a constituent patient 
population that is a large proportion of and demographically similar to PLWHA in the 
US, and has therefore been selected as one of 12 data systems adequate to assess and 
quantify quality of care measures (including retention in clinical care) that will serve as 
benchmarks for progress in the NHAS and Affordable Care Act.(3) 
 




Retention in clinical care has been defined in the IOM recommendations on indicators of 
HIV care as 2 visits within a 12-month period (>90 days apart), either measured by 
laboratory collection as a proxy or directly by clinical encounters.(3) In addressing the 
agreement between retention defined by laboratory measures vs. clinic encounters, the 
time scale over which longitudinal measures are assessed can be defined as elapsed time 
from patient entry to care, calendar time alone (serial cross-sectional assessments of 
retention), or a combination of these methods across two time axes.  Under the hybrid 
method or the calendar time method of assessment, a patient may be classified as 
successfully retained in a calendar period based on clinic encounters, based on laboratory 
measures such as CD4 count or HIV-1 viral load alone, based on both, or may not qualify 
as retained in care by either laboratory measure or encounters. An individual may, at the 
same time, have more laboratory measures than encounters, more encounters than 
laboratory measures, or the same number of each in a given period.   
 The relationship between individual demographic characteristics, clinic 
characteristics, retention in clinical care, markers of individual immune health, receipt of 
ART, substance abuse behavior, and disease or death is likely quite complex with 
individual- and clinic-level factors influencing each of the other factors and immune 
health and substance abuse behavior influencing present and future states of clinical care 
and disease progression while themselves being affected by prior states of care. The 
effect of CD4 count and HIV-1 viral load (as markers of immune health) and the effect of 
substance abuse (indicated by clinical diagnosis) on clinical retention over time could 
also be encapsulated by a time-varying joint-effects framework (Figure 1-1).  The same 
can be said of patients engaging in substance abuse behavior: depending on the ongoing 
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nature of their behavior, it may influence their likelihood of returning to care, while their 
retention in care may bring them into contact with resources capable of helping them alter 
their substance abuse behavior.  And for all that, ongoing substance abuse behavior 
affects the patient’s health directly, too.(41) Therefore, to accurately quantify the 
association of individual- and clinic-level factors with clinical retention, the mediating 




Analysis of data contributed in the NA-ACCORD from 2000 through 2009 have shown a 
small but substantial decrease, from 11% to 7%, in the percentage of patients 
experiencing suboptimal retention (at least one gap in clinical retention defined in line 
with the HRSA HAB measure) in North America over time. A test for trend using GEE 
(to account for clustering of outcomes by individual) showed the decline to be 
statistically significant.  These trends varied by contributing cohort, and in mixed effects 
modeling to account for individual clustering within cohorts, there was non- zero 
variance in the slope term for cohort site (indicating some geographic heterogeneity in 
the outcome).  There has simultaneously been a significant increase in the percent of 
patients retained over the same time period (Figure 1-2).(42,43)  Aims 1, 2, and 3 expand 
on these analyses to include assessments of clinical retention and its relationship with 
various patient characteristics while accounting for site-specific influences and 
geographic clustering. 
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 Multiple modeling approaches, including beta-binomial,(44) zero-inflated  
binomial,(45) logistic mixed effects,(46,47)and Markov transition regression(48,49) revealed 
considerable clustering of individual patient behavior over time (i.e., with poor retention 
historically were likely to continue with poor retention throughout the study period), and 
highlighted male sex, minority racial group, younger age, history of injection drug use, 
and lack of ART receipt as factors associated with suboptimal retention (Table 1-1).  
These findings are consistent with prior research and shows that they are fairly consistent 
across larger geographic areas. 
 
Data collection for clinical population and eligibility criteria  
 
The NA-ACCORD has completed 6 waves of data collection, the latest occurring in 2012 
(covering data through December 31, 2010 for most contributing cohorts).  The study 
population for Aims 1, 2, and 3 was comprised of those individuals with encounter data 
available at least once between January 1, 2000 and December 31, 2010.  For Aim 2, the 
additional inclusion criteria of being ART naïve, initiating ART while in care between 
2000 and 2006, and having at least one CD4 count between ART initiation and loss of 
retention were applied.  For Aim 3, the additional inclusion criteria of available 3-digit 
zip code data and residence within one of four US Census Bureau-defined geographic 
regions were applied. Exclusion criteria were participation in a non-clinical cohort (e.g., 
participation in an interval cohort such as the Multicenter AIDS Cohort Study), age <18 
years, or lack of encounter data during the study period. 
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Assessment of mediating factors and interactions between patient characteristics 
and retention outcomes 
 
 As described above, changes in patient health status over time (indicated by CD4 
count) were considered potentially mediating for the relationship between other clinical 
or demographic factors and the outcome of optimal retention.  These laboratory measures 
were available in the standard data already collected by the NA-ACCORD. Changes in 
substance use diagnoses over time, though potentially a time-varying mediator of the 
exposure-outcome relationship, were only assessed in the course of normal medical care 
and through medical diagnostic information currently collected, not based on Diagnostic 
Statistical Manual criteria,(40) and were therefore excluded as adjustment factors due to 
potential misclassification which would tend to dilute observed effects.  Baseline IDU 
history was instead accounted for in each model. 
  
Study variables and definitions 
 
For Aims 1, 2, 3, the outcome was based on the binary state of retention in care, anchored 
in calendar time, and was defined as adherence to the HRSA HAB, IOM, and NHAS 
measures between entry to the study population (first clinic encounter during the study 
period) and December 31, 2010.  As described above, adherence to the definition was 
assessed in every calendar year: if there were ≥2 HIV primary care encounters, >90 days 
apart, during the calendar year, that year met the criteria for “retention” and was so 
designated.  Death during the study period (either while receiving care or after being lost 
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to follow-up) was treated as a competing event or “absorbent state”, as it must be since 
patients are no longer eligible to be “optimally retained” in care after death.  Individual-
level factors such as age, race, sex, 3-digit zip code of residence, state of residence, 
region of residence, census-derived measures for the area of residence at each of those 
levels, laboratory measures, and clinic encounters were analyzed as factors contributing 
to, mediating, or confounding the relationship between multiple exposures and optimal 
retention.  Antiretroviral therapy (ART) was defined as any regimen consisting of 3 
antiretroviral agents, so long as they were not the triple-nucleoside regimens 
abacavir+tenofovir+lamivudine or didanosine+tenofovir+lamivudine; regimens 
containing both zidovudine and stavudine were excluded because of their 
contraindication with one another. 
 
Overview of this dissertation 
 
This dissertation is organized as three publishable manuscripts comprising Chapters Two, 
Three, and Four.   
 
Chapter Two quantifies the between-measure agreement for laboratory measure-based 
and encounter-based retention metrics between 2000 and 2010, appropriately accounting 
for repeated outcomes within individuals over time and confounding by individual- and 
site-specific factors.  These findings correspond to Specific Aim 1. Preliminary results of 
these findings have been presented at the 18th International Workshop on HIV 
Observational Databases in March 2014. 
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Chapter Three assesses disparities in time from ART initiation until first discontinuation 
of retention from care by patient demographic and risk factors (i.e., sex, race, and HIV 
acquisition risk factor), accounting for death while retained in care as a competing risk. It 
also examines the influence of age on the relative times until discontinuation and the 
influence of mediating immune health status on discontinuation of retention after therapy 
initiation. 
 
Chapter Four examines the geographic distribution of retention outcomes in this cohort 
across the United States and addresses changes in these patterns over time. The effect of 
residence-related factors on the retention experiences of individuals are also addressed 
utilizing multiple analytic techniques at the individual-, 3-digit postal code-, state-, and 
region-levels. Preliminary results of these findings have been presented at the 18th 
International Workshop on HIV Observational Databases in March 2014. 
 
As policy makers, public health practitioners, and epidemiologists train their focus on 
improving HIV outcomes across the HIV care continuum, and in particular, on measuring 
changes in retention among populations of concern in the HIV epidemic, critically 
evaluating the validity of endorsed metrics, the ongoing disparities in the experience of 
HIV care, and the differential impact of individual and geographic factors on retention 
patterns would appear to be rational goals.  This dissertation attempts to address these 
questions on a scale of geography and time that is currently lacking in the scientific 
literature, and in so doing, to provide epidemiologic evidence for improving both the 
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practice of epidemiology in measuring HIV care continuum outcomes and the focus of 
public health actions on populations among whom disparities persist and interventions 




Table 1-1. Odds Ratios (OR) and 95% Confidence Intervals (95% CI) for factors associated with suboptimal clinical retention 




OR        (95% CI) 
Beta-binomial 
 
OR       (95% CI) 
Zero-Inflated 
Binomial 
OR        (95% CI) 
Mixed Effects, 
Intercepts Only 
OR        (95% CI) 
Mixed Effects, 
Intercepts & Slopes 
OR       (95% CI) 
Multiple Logistic, 
Any vs. No “Gaps” 
OR         (95% CI) 
Female Sex 0.91 (0.88, 0.94) 0.96 (0.92, 1.01) 0.92 (0.88, 0.95) 0.95 (0.89, 1.02) 0.96 (0.89, 1.02) 0.94 (0.91, 0.97) 
Age  
(per 10 y) 0.87 (0.86, 0.88) 0.79 (0.77, 0.80) 0.84 (0.83, 0.85) 0.70 (0.69, 0.72) 0.71 (0.69, 0.73) 0.77 (0.76, 0.78) 
Non-Hisp. Black 
(vs. Non-Hisp. White) 1.03 (1.00, 1.06) 1.26 (1.21, 1.32) 1.16 (1.12, 1.20) 1.38 (1.30, 1.46) 1.38 (1.30, 1.46) 1.26 (1.23, 1.30) 
IDU Risk 
(vs. non-IDU) 1.20 (1.17, 1.24) 1.58 (1.51, 1.64) 1.33 (1.29, 1.38) 1.95 (1.83, 2.07) 1.93 (1.82, 2.05) 1.59 (1.55, 1.63) 
ART  




0.96 (0.95, 0.96) 1.13 (1.12, 1.14) 1.11 (1.11, 1.12) 1.17 (1.17, 1.18) 1.18 (1.17, 1.18) 1.12 (1.12, 1.12) 
Markov chain transition among 56,963 individuals after first year in care and conditioned on care status in prior year; all other models among 61,438 
individuals contributing >1 HIV-lab between 2000 and 2008 
Time since enrollment: years under clinical observation in NA-ACCORD 
Mixed Effects model random intercepts are by individual and random slopes are by contributing cohort 
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Laboratory measures are imperfect proxies of primary care encounters: implications for 





Background: Retention in clinical care is identified as a priority for the U.S. National 
HIV/AIDS Strategy.  Due to data limitations, retention is often estimated using laboratory 
measure (e.g., CD4) dates as proxies for clinic encounters. Here we compare calendar 
trends in encounter- versus laboratory-based definitions of retention in a large North 
American HIV cohort collaboration. 
Methodology: The study population included 83,041 HIV+ adults with ≥1 HIV primary 
care encounters during 2000-2010 from 14 North American HIV cohorts. Encounter-
based retention (ER) was defined using the Institute of Medicine’s clinical indicator: >2 
encounters in a calendar year, ≥90 days apart. Laboratory-based retention (LR) was 
defined similarly, but using dates of CD4+ or HIV-1 RNA measurements, not encounters. 
Kappa statistics (κ) were used to describe agreement between ER and LR and logistic 
regression with Generalized Estimating Equations (GEE) and stabilized Inverse 
Probability of Selection Weights (IPW) was used to assess temporal trends and LR’s 
discriminatory power as predictor of ER. Age, sex, race/ethnicity, and HIV risk were 
used as additional predictors in the adjusted model. 
Results: Using ER, 67% (20,591/30,741) and 78% (26,701/34,205) were retained in 
2000 and 2010, respectively. Using LR, 65% (20,020/30,741) and 77% (26,357/34,205) 
were retained in 2000 and 2010, respectively. There were increases with both metrics, 
though there were higher levels of retention by ER throughout (p<0.01 for trend). There 
was fair agreement between ER and LR over time (80-86% agreement, κ=0.55-0.62, 
p<0.01). LR had a strong, but imperfect, ability to discriminate between those retained vs. 
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not by ER (c-statistic=0.81, p<0.05). The sensitivity and specificity of LR as a proxy for 
ER were 84% and 77%, respectively, and a discordance of 18%. LR’s discrimination 
improved in the adjusted model (c-statistic=0.87, p<0.05). Results were similar in shorter 
periods (2000-2003, 2004-2007, and 2008-2010), though discordance by LR was higher 
in earlier periods (18% and 19%, respectively) than in the most recent (16%).  
Conclusions: Clinical retention by both ER and LR improved over time and were 
strongly correlated. However, LR was an imperfect surrogate for ER. The discordance 
between encounter retention status and widely used laboratory proxies provides further 
motivation for integrated health information exchanges and new data sharing techniques 





Retention in clinical HIV care has been widely recognized as a key component in 
improving HIV disease outcomes in individuals and decreasing HIV transmission in 
populations. It is a core indicator of quality care for HIV-1 infected individuals and the 
central feature of the HIV care continuum, following linkage to care and preceding 
receipt of antiretroviral therapy.(1-4) Measures of retention in clinical care have varied 
depending on the available data and the population under study, and various 
demographic, clinical, and environmental characteristics have been observed influencing 
patterns of care over time.(5-7) In 2010, the National HIV/AIDS Strategy (NHAS) for the 
United States advocated improvement in clinical retention rates and, in 2012, the Institute 
of Medicine (IOM) outlined measures for assessing both the NHAS and benchmarks in 
the Affordable Care Act.(8,9) More recently, the Department of Health and Human 
Services adopted process indicators for HIV care and the President of the United States 
issued an Executive Order directing the Office of National AIDS Policy to coordinate a 
Federal response to improve engagement across the continuum as part of the HIV Care 
Continuum Initiative.(10-12) 
There is clearly an increased policy emphasis on improving clinical retention, and 
thus more important than ever to correctly quantify retention at the national, state, and 
local levels, so that progress toward established benchmarks can be accurately assessed. 
Laboratory measures have been widely used as surrogates for care when encounter data is 
unavailable as is often the case in larger studies or with population sampling across 
counties or states and shown to be good indicators of initial or overall access to clinical 
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HIV care.  However, to date, there have been no longitudinal studies establishing the 
actual concordance or correlation between measures of clinical retention defined by 
encounters or primary care visits and those using laboratory measures as surrogates 
among HIV-infected individuals over time.(3,9,13-15) With the wide use of laboratory 
measures as indicators of access to clinical care, the need to accurately quantify retention 
means that agreement across measures which may be based on varying data sources 
should be clarified, so that policymakers, researchers, and other consumers of 
epidemiologic information can better understand and interpolate the clinical care 
experience indicated by alternative measures.  
This research therefore seeks to quantify the concordance of laboratory measures 
(used as surrogates for direct measures of clinical encounters) with actual clinical 
encounters between 2000 and 2010 in a large, demographically, clinically, and 




Population and study design 
 The North American AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD), the North American region of the NIH-sponsored International 
epidemiologic Databases to Evaluate AIDS (IeDEA) project, is a collaboration which 
began collecting data from multi- and single-site interval and clinical cohorts in 2006.(16) 
According to the IOM, the NA-ACCORD has demonstrated a constituent patient 
population that is a large proportion of and demographically similar to PLWHA in the 
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US, and has therefore been selected as one of 12 data systems adequate to assess and 
quantify quality of care measures (including retention in clinical care) that will serve as 
benchmarks for progress in the NHAS and Affordable Care Act.(9) Clinical and 
demographic data from 25 cohorts (including multiple laboratory values and collection 
dates, medical diagnoses and dates, antiretroviral medication names and prescription 
dates, clinic encounter information, basic insurance status, and 3-digit zip code) are 
transmitted to a centrally-administered Data Management Core semi-annually where all 
contributed datasets are harmonized. Data undergo quality control for completeness and 
accuracy, including measures to reduce the probability that an individual was 
concurrently participating in more than one clinical cohort. Both historic clinic encounter 
and laboratory collection data were included in the latest round of data collection 
protocols for 2011 (spanning the period 2000 to 2010). The activities of both the NA-
ACCORD centrally and each participating cohort have been reviewed and approved by 
their respective local institutional review boards.  Further details on the NA-ACCORD 
collaboration have been published previously.(16)  
Among clinical cohorts, only patients with ≥ 2 clinic visits within 12 months were 
enrolled into the NA-ACCORD, limiting the NA-ACCORD clinical population to 
patients established “in care” proximal to cohort entry; this is assessed by sites based on 
clinic encounter data.  For this analysis, we further restricted to adult participants who 
had ≥ 1 HIV primary care visit between January 2000 and December 2010. Interval 
cohorts were excluded to allow an exclusive focus on patterns of patient clinical care.  
The 14 included clinical cohorts were comprised of patients from all 50 U.S. states, 
Washington, D.C., Puerto Rico, and 9 of the 13 Canadian provinces.   
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Retention measures, factors associated with retention, and follow-up 
The outcome for this study was encounter-based clinical retention (ER), defined 
as the IOM-based indicator: ≥ 2 encounters within each calendar year, ≥ 90 days apart. 
Laboratory-based retention (LR) was defined in the same fashion as ER was, but using 
CD4+ or HIV-1 RNA measure dates, not encounters as markers of care. Data from 
inpatient visits were excluded.  
Participant age (categorized as <40 years, 40-49 years, 50-59 years, and ≥60 years 
of age), sex, race/ethnicity (categorized as white, black, hispanic, or other/unknown), 
HIV acquisition risk factor (categorized as male sexual contact with men (MSM), 
injection drug use (IDU), heterosexual contact, or other/unknown), receipt of ART for ≥6 
months in a year (≥3 antiretroviral agents from ≥2 classes, or a triple 
nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) regimen containing abacavir 
or tenofovir), CD4+ cell count, HIV-1 RNA and site of clinical care were included in 
analyses as factors by which the agreement between ER and LR may have differed. ART 
receipt, CD4+ cell count, and HIV-1 RNA were excluded from regression analyses due to 
their potential to induce bias as time-dependent confounders of the relationship between 
LR and ER.  All factors were time-varying except for sex, race/ethnicity, and HIV risk 
factor. 
Data from individuals were used to create one observation per year between the 
year of their entry into the cohort and the year of their final encounter or laboratory 
measurement prior to the end of 2010.  The initial year of care in the cohort was excluded 
if the patient entered in the final quarter of a calendar year (and were thus ineligible to be 
“retained” in their year of entry into care).  The year of death was excluded for patients 
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who died before the end of the study (due to individuals not being uniformly at risk for 
the outcome in the year of death, dependent on the timing of their death during the 
calendar year). Follow-up time ranged between a minimum of 1 and a maximum of 11 
years, and individuals could contribute multiple outcomes over the course of the study. 
Statistical models and methods 
Percent agreement, discordance (percent negative agreement), sensitivity, 
specificity, and Kappa statistics (κ) were all used to quantify agreement between ER and 
LR across and within demographic and clinical characteristics.(17) Differences between 
ER and LR within strata of baseline characteristics were detected by χ2 test. Logistic 
regression using a Generalized Estimating Equation (GEE) was used to assess temporal 
trends and construct receiver operating characteristic (ROC) curves with their respective 
c-statistics to assess LR’s discriminatory power as a predictor of ER.(18) A Toeplitz 
correlation structure based on the means of the unstructured covariance for repeated 
outcomes within individuals was used in the GEE regression.(19,20) Stabilized inverse 
probability of selection weights (IPW) for LR based on cohort site, age, sex, 
race/ethnicity, and HIV acquisition risk were then applied to reflect estimates in a 
pseudopopulation reweighted on these characteristics and estimate the marginal 
relationship between ER and LR while accounting for these factors in the regression 
model.(21)  
Additional details of model diagnostics used in the selection and construction of 
the Toeplitz correlation structure for the regression with GEE, the construction and 
implementation of inverse probability of selection weights for the marginal model, and 
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accompanying tables and plots are available in the Appendix. All analyses were 




Among 83,041 adults included in the study population, the median time 
contributed was 4 years (Interquartile Range (IQR): 2-6 years). There were significant 
differences in ER versus LR within every stratum of baseline demographic and clinical 
factors (Table 2-1).  The percent of person-time retained ranged between 60% and 80% 
for both ER and LR by most characteristics, but was lower among those with an HIV risk 
factor of IDU and those not receiving ART for ≥6 months per year.  There was also good 
agreement between measures within strata (77-87% agreement, κ=0.39-0.66, p<0.01, 
Table 2-1).  
For ER changes over time, 67% (20,591/30,741) and 78% (26,701/34,205) were 
retained in 2000 and 2010, respectively. For LR, 65% (20,020/30,741) and 77% 
(26,357/34,205) were retained in 2000 and 2010, respectively (Figure 2-1). There were 
increases by both definitions, though there were higher levels of retention by ER 
throughout (p<0.01 for trend, Figure 2-1). There was again fair agreement between ER 
and LR over time (80-86% agreement, κ=0.55-0.62, p<0.01, Figure 2-1).  
Regression models using GEE, with and without stabilized IPW to account for 
potential variations in practice across clinical sites (ER ranged from 62-85%, and LR 
from 51-79% across sites) and differences across age, sex, race/ethnicity, and HIV risk 
categories, were used to construct ROC curves. Using the area under the curves for the 
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weighted model, LR had a strong, but imperfect, ability to discriminate between those 
retained vs. not by ER (c-statistic=0.81, p<0.05) (Figure 2-2,a). Using the area under the 
curve for the robust adjusted model (incorporating IPW and again adjusting for site, age, 
sex, race/ethnicity, and HIV risk), LR’s discrimination was improved slightly over the 
unweighted model (c-statistic=0.87, p<0.05) (Figure 2-2,b).  Using weighted model 
estimates, the sensitivity and specificity of LR as a proxy for ER in the pseudopopulation 
were 84% and 77%, respectively, which resulted in a discordance of 18% (Table 2-2). 
Results were similar when using predicted probabilities from the weighted regression 
model and in shorter intervals during the study period (2000-2003, 2004-2007, and 2008-
2010), though discordance by LR was slightly higher in earlier periods (18% and 19%, 
respectively) than in the most recent (16%). 
The same approaches applied within subpopulations of special concern, such as 
younger, minority, male, and IDU patients, revealed similar patterns of improving 
retention over time, though agreement between ER and LR was lower among those older 
than 50 years (vs. <50 years old, p<0.05), among males (vs. females, p<0.05), and among 
IDU patients (vs. non-IDU patients, p<0.05) in weighted regression with age-by-LR and 




Retention in care and the movement of patients in and out of care over time 
(known as “churn”) have implications for the epidemiology and management of HIV in 
the United States and Canada, as well as the design, implementation, and evaluation of 
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prevention and treatment strategies.(8,22) Since improved retention has been recognized as 
a critical component of quality HIV care, HIV disease management, and consequently, as 
a means to decreasing HIV transmission through improved virologic control, it is clear 
that measuring clinical retention accurately and refining targets for improvement are the 
necessary next steps. Meeting each of these goals, consistent with the recent emphasis on 
a “test and treat strategy” to rapidly diagnose HIV-infected individuals and engage them 
in continuous care, has been theorized to “bend the incidence curve” of HIV in the US 
and Canada downward.(23,24) 
Using multiple methods to address the levels of agreement between encounter and 
lab-based measures of retention (ER and LR), both across important demographic and 
clinical groups and over time, it is clear that even in a clinically engaged population 
successfully linked to care, using laboratory measures as proxies for clinic encounters 
does not present precisely the same account of clinical care as requested by recently 
adopted indicators.(9,10) Though the frequency of laboratory monitoring may be of great 
concern to a clinician or epidemiologist depending on the condition or needs of the clinic 
population being served, it is not fully equivalent to the frequency of clinic attendance 
even at a less granular level (that of an annually-assessed retention indicator), and may 
not serve the same policy or monitoring purposes despite its utility otherwise.  This is 
denoted in the language of the IOM report, which refers to laboratory measures as 
“proxies” for encounter based measures.  The use of CD4+ cell counts and HIV-1 RNA 
measures to denote retention in care may also be of particular concern as monitoring 
frequency guidelines or state/local reporting practices for HIV-related laboratory 
measures may change over time in different populations.(14,25) However, it is possible that 
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incomplete data due to differences in reporting practices could be ameliorated and 
retention itself improved by the implementation of secure health information exchanges 
or other emerging data sharing solutions.(26,27) Whatever the similarities or differences 
between ER and LR in these different contexts, though, it should at least be clear to 
whomever conducts analyses or consumes the resultant information (e.g., clinicians, 
epidemiologists, or policy-makers) that they are not one and the same.   
That said, the results of this analysis do not show a gaping chasm between ER and 
LR. For monitoring purposes, it may be the case that use of one vs. the other may result 
in different judgments about whether a particular benchmark for clinical retention has 
been met, but the “misclassification error” comparing one to the other is low enough that 
the distinction may not be as important above a particularly high benchmark.  For 
example, The NHAS establishes a goal to “Increase the proportion of Ryan White 
HIV/AIDS Program clients who are in continuous care … from 73 percent to 80 
percent…”, but using results from 2010, a population that is considered 77% successfully 
retained (by LR) may not be meaningfully different for either policy or clinical purposes 
than a population that is 80% retained (by ER).(8) 
There were limitations in this analysis due to characteristics of the population 
under study and the statistical traits of some measures of agreement.  Because of the high 
prevalence of retention in this population, the kappa statistic in particular may return 
artificially low estimates of agreement; this may also occur when the prevalence of the 
outcome is very low.(17) However, multiple measures of agreement and predictive 
discrimination were used to achieve a more complete picture of the relationship between 
ER and LR over time in this population. Another potential limitation of this analysis is 
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that results obtained using the NA-ACCORD clinical patient population may not fully 
represent the continuum of care experienced by patients, particularly if they access 
clinical care outside of the network of clinical sites inside the NA-ACCORD.  Because 
all data are anonymized before being harmonized at the central Data Management Core, 
there is no way of tracking the movement of individuals between cohort sites (though the 
large geographic dispersion of sites makes it likely that individuals are not 
simultaneously accessing care at disparate locations); there may be misclassification error 
in the outcome if patients leave care at a member site and access care through a local 
public health department, private physician’s office, unaffiliated local hospital, or other 
venue, because they may appear to be experiencing suboptimal retention during that 
period even though they are not. However, this would be a shortcoming in any setting 
where there is not a comprehensive, nationally linked medical records or claims database.  
Despite these potential limitations, the NA-ACCORD has a very large sample size that is 
demographically representative of persons living with HIV/AIDS in the US, represents 
individuals living in geographically diverse regions of the US and Canada, and has been 
formally endorsed as an ideal data source to assess progress in the NHAS, which is an 
exercise related to just the sorts of issues addressed above.(9,28) 
Harnessing the resources of North America’s largest collaborative HIV cohort, 
this analysis showed that clinical retention by both ER and LR improved over time and 
were strongly correlated. However, LR was an imperfect surrogate for ER. The 
discordance between encounter retention status and widely used laboratory proxies 
provides further motivation for novel health information sharing strategies and structures 
to facilitate the most accurate assessment of HIV clinical retention indicators possible. 
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Table 2-1. Percent of patients retained in the NA-ACCORD defined by encounters 
and laboratory  measures, and agreement between retention measures, stratified by 
demographic, clinical, and geographic characteristics, 2000-2010  









Kappa Percent Agreement 
Total 7    83,041 (100) 71 67 0.59 80 
Age (years)*       
≤39 35,713 (43) 62 63 0.64 83 
40-49 29,542 (36) 70 67 0.61 83 
50-59 13,863 (17) 77 68 0.53 81 
≥60 3,923 (5) 84 70 0.39 78 
Sex       
Male 67,951 (82) 71 66 0.57 80 
Female 15,090 (18) 69 69 0.57 80 
Race/Ethnicity       
Non-Hisp. 
White 33,207 (40) 72 69 0.56 82 
Non-Hisp. 
Black 34,175 (41) 69 62 0.60 82 
Hispanic 9,510 (11) 72 73 0.64 86 
Other/Unk. 6,149 (7) 70 67 0.59 82 
HIV Risk Factor       
MSM 30,589 (37) 69 74 0.63 85 
IDU 14,329 (17) 69 58 0.58 80 
Hetero 18,908 (23) 68 71 0.65 85 
Other/Unk. 19,215 (23) 76 59 0.49 77 
CD4+ Cell Count (cells/mm3)*     
<200 19,322 (29) 70 69 0.64 85 
200-349 14,718 (22) 73 74 0.63 86 
350-499 12,940 (20) 74 75 0.61 85 
≥500 19,061 (29) 75 76 0.59 85 
HIV-1 RNA (copies/mL)*     
≥200 copies 45,205 (73) 69 68 0.63 84 
<200 copies 16,972 (27) 81 83 0.52 86 
ART Receipt (≥6 months/year)*     
No ART 46,449 (56) 50 42 0.57 79 
ART 36,592 (44) 83 82 0.46 84 
Country of Care       
U.S.A. 79,236 (95) 70 66 0.58 82 
Canada 3,805 (5) 74 75 0.66 87 
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Percent perfectly retained during the study by encounter (i.e., no years “out of care” between cohort entry 
and final encounter) is different from percent perfectly retained by laboratory measure within every stratum 
(χ2 test, p<0.01) 
 
MSM: male sexual contact with men; IDU: injection drug use; Hetero: heterosexual contact; ART: 
antiretroviral therapy (≥3 agents from ≥2 classes or a triple-NRTI regimen containing abacavir or tenofovir) 
 
*In the year of cohort entry
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Figure 2-1. Temporal trends in encounter- and laboratory-based retention 









































Figure 1. Trends in Clinical Retention, North America, 2000−2010
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Table 2-2. Agreement between ER and LR, and discrimination of ER by LR, 
estimated from stabilized IPW constructed using clinic site, age, sex, race/ethnicity, 
and HIV risk factor. 

















468,816  17 86 79 0.63 





468,816 0.87 18 84 77 0.58 
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Figure 2-2 a,b. Receiver operating characteristic (ROC) curves quantifying the 
discrimination of ER by LR, derived from regression models with GEE and IPW.  (a.) 
ROC from robust adjustment for clinic site with IPW (b.) ROC with IPW based on site, 





































































































IPW Regression    0.805
C-Statistic = 0.805 
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Figure 2-3. Odds Ratios and 95% Confidence Intervals for probability of ER 













Estimates & 95% CIs for Encounter−based Retention, by Lab−based Interactions
Interaction by Age, Sex, Race, and Risk


































Whether measured by laboratory collection surrogates or by clinical encounters 
themselves, retention in clinical care has been defined in the IOM recommendations as 2 
visits within a 12-month period (>90 days apart).(9) To assess concordance between 
definitions of retention based on laboratory measures vs. those based on clinic 
encounters, one can use elapsed time since patient entry to care (and subsequently anchor 
to calendar time, a hybrid of assessment on two time axes) to define retention.  Using the 
hybrid method, a patient may fulfill criteria for retention in a calendar period based on 
clinic encounters alone, based on laboratory measures alone, based on both, or may not 
qualify as retained in care by either laboratory measure or encounters.  Further, a patient 
may have more laboratory measures than encounters, more encounters than laboratory 




Appendix Figure 2-1. Conceptual framework for continuity and retention in clinical 
care over time by calendar periods, as defined by laboratory measures or clinical 
encounters, illustrated for two hypothetical patients “A” and “B”. 
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Selection of Toeplitz correlation structure in the GEE context  
The concordance of two longitudinal binary measures can be modeled as odds 
ratios using estimating equations that properly account for within-individual clustering of 
outcomes.(19)  
Further, the lorelogram, defined as LOR(t j ,tk ) logOR(Yij ,Yik ), can be used to 
quantify the degree of within-individual clustering, and when applied to the recurrence of 
ER over time, it is clear that an independence correlation structure within the GEE is 
inappropriate (Appendix Figure 2-2).(29)   
With that understanding, the regression equations for the marginal model and 
associated covariance/correlation structures are explained further below.  
The generalized linear model for the marginal distribution of the outcome Yit  for 
individual i  at time t  (ER in a calendar year) is specified as: 
g( it ) ′x itβ  
where g is the link function (here, the logit, since ER is a binary response), ′x it  represents 
the covariate matrix for individual i  at time t  (including age, sex, race, HIV risk factor, 
and cohort site), it E(Yit | xit ) , and β  is a scalar for the log odds of the response 
(intercept and covariate regression coefficients).  This can also be written as: 
logit( it ) β0 β1xit   
The estimating equation for β with a sample of i 1,...,N  independent clusters with 





−1(Yi − i(β))i 1
N∑ 0 
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where Var(Yit ) φait , the scale parameter is φ , and Ai  is a diagonal matrix with 
appropriate variance functions  as entries.  For the binomial,  
 where .  The unknown parameter  must be estimated using 
moment methods or another set of estimating equations. 
As shown by Liang and Zeger, the estimating equation produces a consistent 
estimate of β , and N1 2( ˆ β − β) has an asymptotic multivariate normal distribution with 



















The sandwich estimator for Σ, which is consistent regardless of misspecification of the 




−1(Yi − i)(Yi − i ′) Vi
−1 ∂ i
∂ ′βi 1
N∑  when β , φ , and are 
replaced by their consistent estimators. 
Finally, the correlation matrix  for an ni × m matrix of the xit  covariates, 
has parameters for the working correlation matrix written as 
ri (ri,12,ri,13,...,ri,1ni ,ri,23,...,ri,ni−1ni ) .  This means the matrix can also be written as 
.  For the independence correlation structure Corr , for the 
exchangeable structure Corr , for the AR1 (autoregressive) strucure 
Corr , for the unstructured matrix Corr  (with each  
estimated separately), and for the Toeplitz structure Corr ; for each of 
55 
these, t  and ′t  are indicators of adjacent timepoints, and t ≠ ′t . The Toeplitz structure has 
equivalent off-diagonal entries ri,kl ri|k− l | .
(20) The estimates for the lower diagonals from 
the working correlation matrices using the above structures in a logistic regression of ER 
on LR with GEE are depicted in Appendix Figure 2-3. 
As an example, with 4 timepoints, the exchangeable correlation matrix can be 
written as: 
1 α α α
α 1 α α
α α 1 α














the AR1 correlation matrix can be written as: 
 
1 α α 2 α 3
α 1 α α 2
α 2 α 1 α
















and the Toeplitz correlation matrix can be written as:  
1 α ζ ξ
α 1 α ζ
ζ α 1 α
















In the models used for this analysis, , ζ , and ξ  are the means of the unstructured 
matrix’s corresponding diagonals. 
 The quasi-likelihood information criterion (QIC), Copula information criterion 
(CIC), area under the receiver operating characteristic curve (c-statistic), and variance 
differences between the model-based and sandwich estimators can be used to assess 
which of the models incorporating the various correlation structures is closest to the true 
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model and which produces the most accurate predictions.(18,30,31) These diagnostics, with 
the exception of the QIC, generally indicated in this analysis that the Toeplitz correlation 
structure was superior to the independence, exchangeable, AR1, and unstructured 
structures (Appendix Table 2-1).  
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Appendix Figure 2-2. Lorelogram of encounter-based retention (ER) for 10,628 
individuals with observations present over the entire 11-year study period, showing 








































Appendix Figure 2-3 a,b,c,d. Lower diagonals of the empirical (a.) Exchangeable, 
(b.) AR1, (c.) Unstructured, and (d.) Toeplitz correlation matrices derived from 
models of ER predicted by LR.  The Toeplitz bands are the means of the Unstructured 
matrix. 





c.        d.

























10 9 8 7 6 5 4 3 2 1
0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23
0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 NA
0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 NA NA
0.23 0.23 0.23 0.23 0.23 0.23 0.23 NA NA NA
0.23 0.23 0.23 0.23 0.23 0.23 NA NA NA NA
0.23 0.23 0.23 0.23 0.23 NA NA NA NA NA
0.23 0.23 0.23 0.23 NA NA NA NA NA NA
0.23 0.23 0.23 NA NA NA NA NA NA NA
0.23 0.23 NA NA NA NA NA NA NA NA
































10 9 8 7 6 5 4 3 2 1
0 0 0 0.01 0.01 0.03 0.06 0.12 0.24 0.49
0 0 0.01 0.01 0.03 0.06 0.12 0.24 0.49 NA
0 0.01 0.01 0.03 0.06 0.12 0.24 0.49 NA NA
0.01 0.01 0.03 0.06 0.12 0.24 0.49 NA NA NA
0.01 0.03 0.06 0.12 0.24 0.49 NA NA NA NA
0.03 0.06 0.12 0.24 0.49 NA NA NA NA NA
0.06 0.12 0.24 0.49 NA NA NA NA NA NA
0.12 0.24 0.49 NA NA NA NA NA NA NA
0.24 0.49 NA NA NA NA NA NA NA NA
































10 9 8 7 6 5 4 3 2 1
0.04 0.07 0.09 0.12 0.14 0.16 0.18 0.19 0.29 0.36
0.04 0.1 0.12 0.14 0.18 0.2 0.23 0.27 0.4 NA
0.08 0.13 0.13 0.17 0.2 0.24 0.28 0.34 NA NA
0.13 0.12 0.16 0.21 0.24 0.28 0.35 NA NA NA
0.15 0.16 0.2 0.25 0.29 0.35 NA NA NA NA
0.15 0.18 0.23 0.28 0.35 NA NA NA NA NA
0.19 0.19 0.27 0.33 NA NA NA NA NA NA
0.22 0.23 0.31 NA NA NA NA NA NA NA
0.23 0.26 NA NA NA NA NA NA NA NA
































10 9 8 7 6 5 4 3 2 1
0 0.06 0.09 0.12 0.14 0.16 0.19 0.22 0.27 0.33
0.06 0.09 0.12 0.14 0.16 0.19 0.22 0.27 0.33 NA
0.09 0.12 0.14 0.16 0.19 0.22 0.27 0.33 NA NA
0.12 0.14 0.16 0.19 0.22 0.27 0.33 NA NA NA
0.14 0.16 0.19 0.22 0.27 0.33 NA NA NA NA
0.16 0.19 0.22 0.27 0.33 NA NA NA NA NA
0.19 0.22 0.27 0.33 NA NA NA NA NA NA
0.22 0.27 0.33 NA NA NA NA NA NA NA
0.27 0.33 NA NA NA NA NA NA NA NA









Appendix Table 2-1. Model diagnostics for different correlation structures used to 
model ER based on LR.  Adjusted models account for age, sex, race, HIV risk factor, 
and cohort site. QIC is the Quasi-likelihood Information Criterion of Pan.  CIC is the 
Copula Information Criterion.  AUC is the area under the receiver operating 




















(Adjusted) 0.000189 0.000198 0.000170 0.000170 
QIC (Unadjusted) 406,961 408,526 407,546 407,579 
QIC (Adjusted) 406,812 407,748 407,177 407,206 
CIC (Unadjusted) 3.6 3.55 3.45 3.44 
CIC (Adjusted) 4.43 4.25 4.15 4.15 
AUC for ROC of 
Unadjusted Models 0.805 0.805 0.805 0.805 
AUC Unadjusted 
Model, 2000-2003    0.800 
AUC Unadjusted 
Model, 2004-2007    0.805 
AUC Unadjusted 
Model, 2008-2010     0.808 










Retention by Lab 15.43 13.27 14.38 14.34 
 
Year of Care 1.04 1.04 1.04 1.04 
 
Interaction of Lab 




Construction of stabilized inverse probability of selection weights 
Inverse probability of selection weights (IPW) are used to address the problem of 
confounding by re-weighting or balancing populations with respect to the exposure, 
conditional on potential confounders, thus eliminating the exposure-confounder link 
when estimating the effect of the exposure on the outcome.  In this analysis, the potential 
confounders of baseline age, sex, race/ethnicity, HIV risk factor, and cohort site were 
used to construct IPW which were then applied to the marginal model estimating the 
agreement between encounter-based retention (ER) and lab-based retention (LR).  These 
were time-fixed confounders, so single weights across all timepoints for an individual 
were used. The weights were also stabilized and truncated at the 5th and 95th percentiles 
to improve balance (Appendix Figure 2-4).  Assuming a model using the untruncated 
weights is unbiased, truncation reduces variance at the expense of increasing bias in the 
final estimates of effect, but the modest truncation at the 5th and 95th percentiles is 
justified here by the reduction of several orders of magnitude in the 1/minimum and 
maximum weights.(32) 
The weights themselves were constructed using regression to estimate the 
probability of exposure, conditioning on the appropriate confounding factors.  Because 
the exposure of interest was LR, a logistic regression model was used to create the IPW.  
The regression model for the stabilized weights was specified as: 
IPWi
Pr(LRi 1)
Pr(LRi 1 | agei,sexi,racei,riski,sitei)
 
The truncated weights based on site alone (as above, but excluding age, sex, race, 
and risk factor as potential confounders) had a median of 0.92 (interquartile range of 
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0.69-1.17) and a range of 0.25-2.62 (indicating a lack of extreme values which might lead 
to unstable effect estimates).  The truncated weights based on all potential confounding 
factors available had a median of 0.92 (interquartile range of 0.65-1.16) and a range of 
0.20-2.72.  The untruncated and truncated distribution of weights accounting for site 
alone and for all available confounders are illustrated below (Appendix Figure 2-4). 
Using these weights, the regression of ER on LR with GEE was conducted (as 
outlined above) to adjust for the potential confounding factors and account for clustering 
of outcomes within individuals while retaining a marginal estimate for the association 
between ER and LR. 
 





Appendix Figure 2-4 a,b. Distribution of constructed IPW for the probability of LR, 
both untruncated and truncated at the 5th and 95th percentiles, (a.) based on clinic 
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Race, Sex, and HIV Risk Disparities in Loss of Clinical Retention after ART Initiation in 










Background: While retention in clinical care has been identified as a key component of 
the HIV continuum of care, race, sex, and HIV risk disparities in retention and other HIV 
outcomes have been noted by multiple researchers in the U.S.  Retention is a dynamic, 
non-linear process in the continuum of care through which patients may receive 
antiretroviral therapy (ART) and be successfully virologically suppressed, without which 
patients may progress to AIDS and/or death. Here, we examined disparities in 
discontinuation of care after the initiation of ART by race, sex, and HIV risk factor 
among patients in a large collaborative cohort in North America. 
Methods: The study population included 17,171 HIV+ adults with ≥1 HIV primary care 
encounters during 2000-2010 and initiating ART in one of 13 North American AIDS 
Cohort Collaboration on Research and Design (NA-ACCORD) clinical cohorts. 
Discontinuation of clinical retention was the event of interest and was defined as failure 
to comply with the Institute of Medicine’s indicator: ≥2 encounters in a calendar year, 
≥90 days apart. Follow-up began at the date of ART initiation and ended at the first of: 1) 
the last visit in the first calendar year in which retention was interrupted (first 
discontinuation); 2) date of death; 3) the end of the study period (if the patient neither 
discontinued care nor died before December 31, 2010).  Differences in categorical and 
continuous variables by race, sex, and HIV risk factor were described by χ2 and Kruskal-
Wallis tests, respectively.  Cox proportional hazards regression models were used to 
assess relative hazards (HR) with 95% Confidence Intervals (95% CI) and compare times 
from ART initiation until discontinuation of retention by race, sex, and HIV risk 
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categories, adjusting for potential confounding factors and treating death before 
discontinuation of care as a competing event. Baseline age, baseline CD4+ lymphocyte 
count within one year of ART initiation, and cohort site were adjusted for as confounding 
factors in the full model. 
Results: Among 17,171 adults initiating ART while in clinical care in the NA-ACCORD, 
the median follow-up time was 3.97 years (Interquartile Range (IQR): 1.85-6.21 years).  
During the study period, 49% of participants experienced the event of interest (8,367 / 
17,171), 9% died before discontinuing care (1,511 / 17,171), and 43% were right 
censored without experiencing any event (7,293 / 17,171).  There were significant 
differences in the distribution of events by race, sex, and history of injection drug use 
(IDU) as HIV risk factor. In adjusted Cox regression models, the cause-specific hazard of 
discontinuation from retention was lower for females vs. males (HR: 0.81; 95% CI: 0.77, 
0.86) and higher for Black vs. non-Black patients (HR: 1.18; 95% CI: 1.13, 1.24) and for 
those with IDU vs. non-IDU risk (HR: 1.35; 95% CI: 1.28, 1.43). The cause-specific 
hazard for the competing event (death) was lower for females vs. males (HR: 0.79; 95% 
CI: 0.66, 0.93) and higher for Black vs. non-Black patients (HR: 1.16; 95% CI: 1.04, 
1.29) and for those with IDU vs. non-IDU risk (HR: 1.16; 95% CI: 1.02, 1.31). Median 
times to discontinuation were lower for Black vs. non-Black patients (5.42 vs. 6.37 years) 
and for those with IDU vs. non-IDU risk (5.27 vs. 6.46 years); there were no differences 
in adjusted median times to discontinuation by sex. 
Conclusions: Racial and HIV risk disparities in clinical retention persisted after 
accounting for the competing risk of death, access and linkage to care, access to therapy, 
CD4+ lymphocyte level at the time of ART initiation (accounting for “lateness” of 
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initiation), immune health changes after initiation of ART, and the age structure of the 
clinical population. Though there are no sex disparities in retention after adjustment for 
age and other factors, males progress to death faster than females even after receiving 





Retention in clinical care has been identified as a key component of the HIV 
continuum of care, though race, sex, and HIV risk disparities in retention and HIV 
disease outcomes have been noted by multiple researchers in the U.S.(1-9)  Retention is 
also part of the dynamic, non-linear continuum of care. Even once patients gain access to 
antiretroviral therapy (ART) after linkage and engagement in care, they may 
subsequently progress toward virologic suppression and improved outcomes or toward 
AIDS and/or death, all while maintaining clinical retention or repeatedly dropping out of 
and re-entering care.(10)  
Race, sex, and HIV acquisition risk factor are obviously not traits that can be 
modified to alter the trajectory of disease. Hence, the epidemiologic question treated here 
is not one of causal effect but rather the identification of disparities that can be used for 
surveillance of HIV care in vulnerable and high-risk populations and for focusing policy 
or funding toward those groups that may require more intensive interventions or 
resources. Further, research on retention that has assessed populations with differing 
access to ART or medical care in general have found these to be important factors 
associated with retention; in these same studies, poorer immune health has been a 
powerful predictor of improved retention independent of other characteristics, though at 
least one recent study in a large private care setting found that lower CD4+ lymphocyte 
count was associated with increased likelihood of missed visits.(11-15) In particular, studies 
examining sex differences in retention or interruption of therapy after balancing 
populations on access to care have frequently taken place in the context of clinical trials, 
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in resource-limited settings, or else at single clinical sites not reflective of the real-world 
patterns of clinical care experienced by patients across North America.(16-19) In addition, a 
recent systematic review has noted mixed evidence for sex disparities dependent on the 
HIV outcome being examined, with a disparity present for all-cause mortality but not for 
progression to AIDS or other clinical outcomes.(20)  Where racial and HIV risk disparities 
in retention and HIV outcomes are concerned, many of the aforementioned studies have 
also noted significant differences by Black race and IDU risk factor,(3,6,7,11,13,15) though at 
least one clinical cohort has noted a disappearance of racial disparities in HIV outcomes 
in its recent history.(21) 
Therefore, to minimize potential confounding of the relationship between 
demographic and risk factors and retention in clinical care by access to ART, and in order 
to address racial, sex, and risk disparities in HIV outcomes and retention in a broader 
population of individuals reflective of a more typical clinical care experience in North 
America, we examined disparities by these factors in discontinuation of care after the 
initiation of ART while accounting for immune health at and subsequent to initiation of 




Population and study design 
The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) is a multi-site collaboration of interval and clinic-based cohort studies of 
HIV-infected individuals receiving care in the US and Canada.(24) NA-ACCORD is one 
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of the regional cohort studies sponsored by the National Institute of Health‘s International 
epidemiological Databases to Evaluate AIDS (IeDEA) consortium. The Institute of 
Medicine (IOM) has identified the NA-ACCORD as comprising a large proportion of and 
demographically similar patient population to persons living with HIV/AIDS (PLWHA) 
in the US, and has therefore endorsed the NA-ACCORD as one of 12 data systems 
appropriate to assess quality of care measures (including retention in care) in monitoring 
progress in the National HIV/AIDS Strategy and Affordable Care Act.(5) Details on the 
NA-ACCORD collaboration and participating cohort studies have been published 
previously.(25) Briefly, each contributing cohort has developed standardized cohort-
specific methods of data collection.  At scheduled intervals, these cohorts submit data 
regarding enrolled participants’ demographic characteristics, vital status, prescribed 
antiretrovirals, clinical diagnoses, and dates and results of laboratory tests including HIV-
1 RNA viral load and CD4 lymphocyte count (HIV-lab).  HIV-lab dates are submitted as 
dates of specimen collection, not dates of assay performance, and among clinical cohorts, 
only patients with ≥2 clinical visits within 12 months are enrolled into the NA-ACCORD.  
Death is determined locally by contributing cohorts using NDI, SSDI, state, and local 
sources, including death certificates and electronic medical records.  These data are 
transferred securely to the NA-ACCORD’s central Data Management Core, where they 
undergo extensive quality control for completeness and accuracy per a standardized 
protocol before they are combined into harmonized data files.  Quality control included 
instituting measures to reduce the probability that an individual was concurrently 
participating in more than one clinical cohort.  The human subjects activities of the NA-
ACCORD and each of the participating cohort studies have been reviewed and approved 
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by their respective local institutional review boards. Each cohort study has likewise 
received permission to participate in the NA-ACCORD through the same review and 
approval process. 
Inclusion criteria and variables of interest. 
 Participants in the clinical cohorts of the NA-ACCORD that submitted primary 
care encounter, race/ethnicity, sex, and HIV acquisition risk data were included in this 
analysis, allowing us to focus on patterns of care retention as measured by IOM 
guidelines for HIV clinical care and assess competing risks of discontinuation of care vs. 
all-cause mortality by racial, sex, and HIV risk group. The interval cohorts in the NA-
ACCORD that have independently structured visit schedules by definition, and are 
therefore not necessarily reflective of clinical practice, were not included in the study.  
The 13 included cohorts have clinical sites in 50 US states, Washington D.C., Puerto 
Rico, a Canadian province, and are comprised of patients residing in all 50 US states, 
Washington D.C., Puerto Rico, and 5 Canadian provinces.   
 We analyzed data from ART-initiating HIV-infected adults (≥18 years of age) 
who had ≥1 HIV primary care encounter between January 2000 and December 2010 and 
≥1 CD4+ lymphocyte count after ART initiation but prior to death or first discontinuation 
of retention. 
 Retention in continuous care was defined concordant with the IOM indicator: ≥2 
encounters within 12 months, but >90 days apart, beginning with the year of patient’s 
ART initiation during the study period.  This retention definition was anchored to 
calendar time to create estimates comparable with other studies and clinic-level reports 
applying the indicator in regular reporting intervals.  Discontinuation of retention was 
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defined as failure to meet the IOM indicator definition in any calendar year before exiting 
the study.  ART initiation was defined as the first recorded regimen of ≥3 antiretroviral 
agents from ≥2 classes, or a triple nucleoside/nucleotide reverse transcriptase inhibitor 
(NRTI) regimen containing abacavir or tenofovir, received following entry to care and 
with no recorded HIV-1 RNA measures <200 copies/mL preceding, among treatment 
naïve individuals.    
Event of interest, competing event, and follow-up 
 The outcome or event of interest was first discontinuation of retention in care 
before the end of the study (December 31, 2010).  The competing event was all-cause 
death, creating a complementary and exhaustive mix of events (e.g., all participants are 
expected to eventually experience one of the two events).  Baseline was ART initiation 
and the time origin for the analysis was 1 year after ART initiation (denoted as ART 
initiation +1) because most participants were not truly at risk for a discontinuation in care 
until exiting this window.  In other words, because ART initiation and clinical encounters 
were likely tethered by definition, and discontinuation required a >12-month lapse from 
the most recent prior encounter, the year of ART initiation was essentially immortal 
person-time for this outcome.  To create a comparable population for the competing 
event, participants with deaths within 1 year after ART initiation were excluded.  Patients 
with neither event by study end were administratively censored. 
Exposures of interest and factors associated with death and discontinuity in retention 
Self-reported year of birth, race/ethnicity, HIV transmission risk group, sex, 
CD4+ lymphocyte count within 1 year prior to ART initiation, CD4+ lymphocyte nadir 
after ART initiation, and median CD4+ lymphocyte count in each year after ART 
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initiation were identified as factors potentially associated with death and discontinuation 
of retention. Sex was categorized as female or male (transgender patients are excluded 
from participation in NA-ACCORD). Race/ethnicity was categorized as Black or non-
Black (including other/unknown).  HIV transmission risk group was categorized as 
injection drug use (IDU) or non-IDU (including men who have sex with men (MSM), 
heterosexual contact, and other/unknown).  Patients with both sexual and IDU 
transmission risk were categorized as IDU. Patients were classified as using ART if the 
patient was prescribed ART for ≥1 month in a calendar period; measures of adherence to 
HIV treatment were not available. 
Statistical Methods 
The primary objective of the analysis was to determine whether the risk of first 
discontinuation of retention after ART initiation in the NA-ACCORD clinical population 
differed by sex, racial group, or HIV risk group, while recognizing that death was a 
competing risk for discontinuity. 
Bivariate comparisons of patient characteristics and event-types by exposure 
status (female vs. male, Black vs. non-Black, and IDU vs. non-IDU) were conducted 
using the χ2 test for categorical variables or the Kruskal-Wallis test for continuous 
variables.   
A competing risks analysis of time from ART initiation to first discontinuation in 
clinical care or death by sex, racial group, and HIV risk group was conducted in a cause-
specific hazard context, censoring one event with respect to the other.(26)  The resultant 
cause-specific hazard for the event of interest can be interpreted as the factor by which 
the hazard of discontinuation at any time, t, is different by sex, race, or risk group, among 
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those who haven’t yet died at time t (or vice versa with respect to cause-specific hazards 
of the competing event).   
All models adjusted for age at ART initiation (scaled by 10 years), baseline CD4+ 
lymphocyte count (scaled by 100 cells/mm3), sex, and IDU as HIV risk factor (vs. non-
IDU), as these variables were either the exposures of interest or else potential 
confounders for the relationships between the exposures, discontinuation of retention, and 
all-cause death.  Stabilized Inverse Probability of Selection Weights (IPW) were used to 
produce stratified adjusted survival and cumulative incidence curves in addition to curves 
and estimates produced through direct adjustment for covariates in Cox models. Nadir 
CD4+ lymphocyte count after ART initiation and median CD4+ lymphocyte count in 
each year after ART initiation were used in alternate weighting and regression schema to 
reveal the direct effect of the demographic and risk factors on retention after accounting 
for mediation of this relationship by immune health. Details of the construction, 
truncation, and distribution of weights and checks of the proportionality of hazards 
assumptions may be found in the Appendix.(27-30)  Baseline log10 HIV-1 RNA was 
excluded from analyses as it was unavailable for 2,891 individuals; the effects of baseline 
HIV-1 RNA at ART initiation on the distribution of times to discontinuity or death could 
be modeled effectively following a multiple imputation procedure, but was not performed 
here. All weights were constructed and adjusted models were executed including cohort 
site as a covariate to account for potential differences in clinical practice across sites. 
Analyses were conducted in Stata v. 12.1 (Stata Corporation, College Station, 





Among 17,171 adults initiating ART while in clinical care in the NA-ACCORD, 
the median follow-up time was 3.97 years (Interquartile Range (IQR): 1.85-6.21 years).  
During the study period, 49% of participants experienced the event of interest (8,367 / 
17,171), 9% died before discontinuing care (1,511 / 17,171), and 43% were right 
censored without experiencing the event of interest or the competing event (7,293 / 
17,171).  There were significant differences in the distribution of events by race, sex, and 
IDU as HIV risk factor, though the distribution of times until event were shorter for right 
censoring comparing females to males (median 5.44 vs. 5.87 years, respectively) and 
longer for death comparing IDU to non-IDU status (median 3.16 vs. 2.66 years, 
respectively) (Table 3-1, b and c).  Females were younger than males (median age 42 vs. 
48 years), and patients with IDU risk were older than non-IDU patients (median age 50 
vs. 46 years).  Baseline CD4+ lymphocyte count at ART initiation was lower among 
Black compared to non-Black patients, males compared to females, and non-IDU 
compared to IDU patients (Table 3-1, a, b, and c).  Nadir CD4+ lymphocyte count after 
ART initiation but before first discontinuation, death, or right censoring was lower 
among Black compared to non-Black patients (144 vs. 176 cells/mm3, respectively). In 
adjusted Cox regression models accounting for demographic factors, baseline CD4+ 
lymphocyte count, and nadir CD4+ lymphocyte count after ART initiation, the cause-
specific hazard of the event of interest (discontinuation from retention) was lower for 
females vs. males (HR: 0.81; 95% CI: 0.77, 0.86) and higher for Black vs. non-Black 
patients (HR: 1.18; 95% CI: 1.13, 1.24) and for those with IDU vs. non-IDU risk (HR: 
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1.35; 95% CI: 1.28, 1.43) (Table 3-2, a). The cause-specific hazard for the competing 
event (death) was lower for females vs. males (HR: 0.79; 95% CI: 0.66, 0.93) and higher 
for Black vs. non-Black patients (HR: 1.16; 95% CI: 1.04, 1.29) and for those with IDU 
vs. non-IDU risk (HR: 1.16; 95% CI: 1.02, 1.31) (Table 3-2, b). Median times to 
discontinuation were significantly lower for Black vs. non-Black patients (5.42 vs. 6.37 
years) and for those with IDU vs. non-IDU risk (5.27 vs. 6.46 years) (Figure 3-1, b and 
c); there were no differences in adjusted median times to discontinuation by sex, though 
the adjusted cumulative incidence curve for females was significantly lower than that for 
males by the stratified log-rank test (Figure 3-1, a).  The overall adjusted cumulative 
incidence of discontinuation of retention was 0.74 and for death in care was 0.16 at the 
end of 10 years of follow-up. 
A time-dependent Cox regression accounting for median CD4+ lymphocyte count 
in each year between ART initiation and first discontinuation of retention or death 
showed similar patterns of association between sex, race, risk and the event of interest 
(and competing event), except that the weighted regressions appeared to more closely 
approximate the directly adjusted regressions when incorporating median CD4+ 
lymphocyte count in the weights and the association of female sex with death was no 
longer significant in the directly adjusted model (Table 3-3, a,b).  The differences in 
median times until discontinuation appeared to be larger by sex, race, and risk, and there 
was no association of median CD4+ lymphocyte count comparing the 200-349, 350-500, 
or ≥500 cells/mm3 categories to the <200 cells/mm3 category in the fully adjusted model 
(Table 3-3,a).  There were significantly lower hazards of progression to death comparing 
all higher median CD4+ lymphocyte count categories to the <200 cells/mm3 category as a 
	  83 
reference, which is as expected (higher CD4 should be an indicator of increased 
likelihood of survival) (Table 3-3, b). 
Though the stratified adjusted curves presented are set to the mean of the 
covariates, they are useful to describe the sex, race, and risk differences in median times 
to discontinuation of retention, accounting for the competing risk of death.  Further, they 
are similar in shape to the weighted curves which are simply stratified by the exposure of 
interest (Figure 3-1).  The stratified predicted cumulative incidence curves for 
discontinuation of care by sex, adjusted only by scaled baseline age, estimated at the 
quartiles of the sample age distribution (39.7, 47.1, and 55.0 years) is also provided to 
demonstrate the confounding influence of age on the association between sex and the 
event of interest; though the unadjusted stratified curve across all ages (Figure 3-1, a) 
shows earlier discontinuation for females vs. males, the stratified curve adjusted for age 
estimated at the quartiles of the age distribution shows earlier discontinuation for males 
vs. females within each age stratum (Figure 3-2, a).  This is the case with IDU vs. non-
IDU risk as well (Figures 3-1, b and 3-2, b).  The older age distribution of males and IDU 
patients in this cohort, and the strong effect of age on retention, explain the observed 
changes in the relative hazards and median times of discontinuation from the unadjusted 




Clinical retention and HIV disparities research have been linked through 
numerous studies describing the relationship between clinical engagement, access to and 
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initiation of therapy, continuity of care, and HIV disease progression in various 
populations and settings, both in resource-rich and resource-limited settings.  Few 
studies, however, have followed a cohort as large as the population observed in these 
analyses over such a long period of time after ART initiation, indeed, a long enough 
period to directly observe the median times of first discontinuation of retention in 
care.(12,13,15,16,18,31-39)   
Here, the analysis of sex, race, and HIV risk factors, by which there have been 
conflicting mentions of disparities in both retention and other HIV disease outcomes, 
again implicates Black race and IDU risk as important factors influencing loss of 
retention.  Though there were apparent differences in retention after ART initiation by 
sex (females leaving care before males) and differences in death in care by Black race 
(Black patients dying sooner than non-Black patients), both of these relationships were 
attenuated and became non-significant after adjusting for age and the mediating factors of 
nadir or median CD4+ lymphocyte counts after ART initiation.  By contrast, the sex 
disparity in death in care persisted after adjustment (with males dying sooner than 
females), and there was a marked difference in both retention and death by HIV risk 
factor (worse outcomes for both events for those with IDU vs. non-IDU risks). 
Because the event of interest here was first discontinuation of retention following 
ART initiation, it is important to note that re-engagement or re-entry into care after 
individuals leave the risk set in this analysis is very possible.  In subsequent analysis, the 
cumulative incidence curve of time from first discontinuation to re-entry (again treating 
death after discontinuation as a competing event for re-entry), shows a fairly rapid re-
	  85 
entry after exit, and the shape of the curve tracks that of the cumulative incidence curve 
for first discontinuation fairly closely (data not shown).   
There were limitations to this analysis.  First, we lacked data on socioeconomic, 
insurance, and other contextual factors which have been shown to be strongly related to 
both retention and HIV disease outcomes in other studies and which may differ by 
demographic or risk group factors.(40,41)  Some studies with single-sex populations have 
noted poverty and housing stability as important influences on retention and ART 
adherence,(42,43) and addressing differences in the quality of care experienced by 
incarcerated populations, while imprisoned and after release, has been found to be 
strongly associated with retention in HIV care.(44) Though publicly available data on 
certain health economic factors such as access to Medicaid by state of patient residence 
or the status of AIDS Drug Assistance Program waiting lists were available for portions 
of the study period, these were felt to be more distal to the individual care experiences of 
the patients under study (for example, acting as broad proxies for individual insurance 
status).  Further, the effects of the absence of these data should have been mitigated by 
the fact that all patients under study were successfully engaged in care (as a prerequisite 
for entering the NA-ACCORD) and had access to ART since they were at least initially 
prescribed a regimen.  The immune status of individuals at ART start was also taken into 
account in the adjusted models, helping to account for complications due to “late” 
initiation of care.  
Second, because of the nature of a harmonized, de-identified study population 
drawing on several independent clinical cohorts, the data available do not represent an 
exhaustive accounting of all sources of HIV care that participants may have accessed 
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outside of the cohort.  This could lead to misclassification of the event of interest if 
patients access clinical care apart from the network of clinical sites inside the NA-
ACCORD (apparently discontinuing care, but in reality still receiving care).  Because 
data is de-linked and de-identified at the central Data Management Core, there is no way 
to trace patient movement between cohort sites or from a cohort site to a clinical center 
outside of the collaborative cohort. A potential mitigating factor for this limitation is that 
the large geographic dispersion of sites makes it unlikely that individuals access care at 
disparate locations simultaneously.  This sort of data limitation also provides motivation 
for improved linkage between medical records or state health department surveillance 
records, perhaps through state health information exchanges. In contrast, ascertainment of 
death (the competing event) is assumed to be complete due to the cohort use of various 
national death indices. 
Despite these limitations, the NA-ACCORD provided a large study population 
that is demographically representative of PLWHA in the US, is comprised of patients 
from varied locations in the US and Canada, and has been endorsed by the IOM as an 
ideal data source with which to evaluate indicators of HIV care such as clinical retention.  
We also used survival modeling techniques that help account for the competing risk of 
death when estimating the hazard of discontinuation from care and obtained information 
over a decade following the initiation of ART. 
 Racial and HIV risk disparities in clinical retention persisted after accounting for 
the competing risk of death, access and linkage to care, access to therapy, CD4+ 
lymphocyte level at the time of ART initiation (accounting for “lateness” of initiation), 
immune health changes after initiation of ART, and the age structure of the clinical 
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population. Though there are no sex disparities in retention after adjustment for age and 
other factors, males progress to death faster than females even after receiving ART and 
remaining successfully retained in care.  These results highlight the fact that the use of 
ART, clinical retention, and disease outcomes (including death) are dynamically linked, 
and successful linkage, engagement, and treatment do not necessarily imply successful 
retention in care or improved disease progression.  Clinical retention must be actively 
pursued- made a priority by clinicians, communities, and public health officials- 
particularly focusing resources on the groups repeatedly identified as being at higher risk 
for discontinuation from care.  The fact that disparities in the clinical experience of HIV 
patients remain, even after accounting for demographic traits, intermediate biological 
factors, and potential differences in access to care, implies that many factors that 
differentially influence clinical retention and disease progression may remain.  It is 
precisely those factors that should be the focus of future research and targeted 
interventions to provide equally high-quality HIV care experiences for all HIV-positive 
individuals. 
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Table 3-1 a,b,c. Characteristic differences and endpoint distributions among 17,171 
ART initiators in the NA-ACCORD, by (a.) black race, (b.) sex, (c.) HIV risk of 
history of injection drug use, 2000-2010 
 
a.  
Characteristic                  Black                  Non-Black P-value* 
Total 7,565 (44) 9,606 (56)  
Time in Follow-Up      
(years) 3.82 (1.8, 6.0) 4.08 (1.9, 6.3) <.001 
Age (years) 47 (40, 55) 47 (39, 55) 0.62 
Sex     <.001 
   Male 5,815 (40) 8,556 (60)  
   Female 1,750 (62) 1,050 (38)  
HIV Risk     <.001 
   Non-IDU 5,731 (41) 8,228 (59)  
   IDU 1,834 (57) 1,378 (43)  
CD4+ Lymphocytes† 




144 (30, 272) 176 (57, 302) <.001 
HIV-1 RNA§ 
(log10 copies/mL) 
4.521 (3.42, 5.13) 4.531 (3.21, 5.17) 0.99 
Event Number Years in FU Number Years in FU P-value* 
Death 738 2.66 (1.51, 4.32) 773 2.88 (1.51, 4.82) 0.17 
Discontinuity in Care 3,830 2.41 (1.42, 4.19) 4,537 2.46 (1.40, 4.22) 0.75 
Event Free 2,997 5.79 (4.23, 7.88) 4,296 5.85 (4.26, 7.92) 0.77 
 
Numbers Presented as "Number (%)" if Categorical, as "Median (IQR)" if Continuous 
* χ2 for Categorical, Kruskal-Wallis for Continuous   
†  At ART initiation, Available for N=14,356 individuals 
‡  After ART initiation, Available for N=17,171 individuals 






Characteristic                  Female                  Male P-value* 
Total 2,800 (16) 14,371 (84)  
Time in Follow-Up      
(years) 3.47 (1.7, 5.7) 4.07 (1.9, 6.3) <.001 
Age (years) 42 (35, 50) 48 (40, 56) <.001 
Race     <.001 
   Non-Black 1,050 (11) 8,556 (89)  
   Black 1,750 (23) 5,815 (77)  
HIV Risk     0.66 
   Non-IDU 2,268 (16) 11,691 (84)  
   IDU 532 (17) 2,680 (83)  
CD4+ Lymphocytes† 




163 (45, 284) 162 (43, 289) 0.83 
HIV-1 RNA§ 
(log10 copies/mL) 
4.398 (3.45, 5.05) 4.548 (3.25, 5.17) 0.01 
Event Number Years in FU Number Years in FU P-value* 
Death 177 2.65 (1.49, 3.95) 1,334 2.80 (1.51, 4.71) 0.13 
Discontinuity in Care 1,525 2.38 (1.40, 4.00) 6,842 2.45 (1.42, 4.24) 0.10 
Event Free 1,098 5.44 (3.88, 7.63) 6,195 5.87 (4.30, 7.96) <.001 
Numbers Presented as "Number (%)" if Categorical, as "Median (IQR)" if Continuous 
* χ2 for Categorical, Kruskal-Wallis for Continuous   
†  At ART initiation, Available for N=14,356 individuals 
‡  After ART initiation, Available for N=17,171 individuals 



















Characteristic                  IDU                  Non-IDU P-value* 
Total 3,212 (19) 13,959 (81)  
Time in Follow-Up      
(years) 3.85 (1.8, 6.1) 3.99 (1.9, 6.2) 0.30 
Age (years) 50 (44, 55) 46 (39, 55) <.001 
Sex     0.66 
   Male 2,680 (19) 11,691 (81)  
   Female 532 (19) 2,268 (81)  
Race     <.001 
   Non-Black 1,378 (14) 8,228 (86)  
   Black 1,834 (24) 5,731 (76)  
CD4+ Lymphocytes† 




160 (48, 281) 163 (42, 290) 0.65 
HIV-1 RNA§ 
(log10 copies/mL) 
4.418 (3.28, 5.05) 4.547 (3.30, 5.17) <.001 
Event Number Years in FU Number Years in FU P-value* 
Death 340 3.16 (1.81, 4.86) 1,171 2.66 (1.47, 4.45) 0.001 
Discontinuity in Care 1,623 2.37 (1.40, 4.20) 6,744 2.46 (1.42, 4.21) 0.48 
Event Free 1,249 5.91 (4.24, 7.99) 6,044 5.81 (4.25, 7.88) 0.26 
  
Numbers Presented as "Number (%)" if Categorical, as "Median (IQR)" if Continuous 
* χ2 for Categorical, Kruskal-Wallis for Continuous   
†  At ART initiation, Available for N=14,356 individuals 
‡  After ART initiation, Available for N=17,171 individuals 
§  At ART initiation, Available for N=14,261 individuals 
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Table 3-2 a,b.  Cause-specific Hazard Ratios (HR) for and median times to (a.) discontinuation of retention and (b.) death 
before discontinuation, with nadir CD4+ lymphocyte count after ART initiation, from unadjusted, adjusted, and weighted Cox 












Median Time*† (Years)  
(95% CI) 
Age (per 10 years) 0.55 (0.55, 0.57) 0.59 (0.57, 0.60)   
Sex      Difference = -0.45 
   Male Ref. Ref. Ref. 5.82 (5.69, 5.94) 
   Female 1.24 (1.17, 1.31) 0.81 (0.77, 0.86) 1.09 (1.02, 1.16) 6.27 (5.82, 6.68)  
Race      Difference = 0.95 
   Non-Black Ref. Ref. Ref. 6.37 (6.14, 6.68) 
   Black 1.12 (1.07, 1.17) 1.18 (1.13, 1.24) 1.14 (1.09, 1.19) 5.42 (5.24, 5.67) 
Risk      Difference = 1.19 
   Non-IDU Ref. Ref. Ref. 6.46 (6.27, 6.66) 
   IDU 1.06 (1.00, 1.12) 1.35 (1.28, 1.43) 1.12 (1.06, 1.19) 5.27 (4.87, 5.63) 
CD4+ Lymphocytes  
(per 100 cells/mm3) 0.99 (0.98, 0.99) 0.95 (0.94, 0.97) 
  
Nadir CD4+ Lymphocytes‡  
(per 100 cells/mm3) 1.04 (1.03, 1.05) 1.06 (1.05, 1.08) 
  
Stratified Log-Rank Test (Score) Unadjusted Adjusted Weighted P-value*† 
Female Sex 58.0 3741 6.17 <.001 
Black Race 26.0 3769 32.4 <.001 
IDU Risk 4.3 3797 14.8 <.001 
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Bold results are significant (p<0.05) 
 
Estimates of median time differences are from Cox models stratified on the characteristic of interest, adjusting and weighting by all other variables, including 
cohort site, and holding covariates at their mean values 
 
All variables are measured at ART initiation, except for Nadir CD4+ Lymphocyte count 
 
*Adjusted model includes all factors described in the table and cohort site 
 
†Inverse Probability of Selection Weights for Sex, Race, and Risk constructed using all other covariates with the addition of cohort sub-site (to account for 
potential differences in clinical practice between sites) 
 
















Median Time*† (Years)  
(95% CI) 
Age (per 10 years) 1.10 (1.05, 1.15) 1.07 (1.02, 1.13)   
Sex       
   Male Ref. Ref. Ref. >10 Years 
   Female 0.74 (0.64, 0.87) 0.79 (0.66, 0.93) 0.73 (0.60, 0.87)  
Race       
   Non-Black Ref. Ref. Ref. >10 Years 
   Black 1.27 (1.15, 1.41) 1.16 (1.04, 1.29) 1.19 (1.07, 1.32)  
Risk       
   Non-IDU Ref. Ref. Ref. >10 Years 
   IDU 1.28 (1.13, 1.44) 1.16 (1.02, 1.31) 1.29 (1.13, 1.47)  
CD4+ Lymphocytes  
(per 100 cells/mm3) 0.85 (0.83, 0.88) 0.99 (0.96, 1.02) 
  
Nadir CD4+ Lymphocytes‡  
(per 100 cells/mm3) 0.70 (0.67, 0.73) 0.71 (0.67, 0.74) 
  
Stratified Log-Rank Test (Score) Unadjusted Adjusted Weighted P-value*† 
Female Sex 13.7 391.9 11.9 <.001 
Black Race 21.8 385.7 10.9 <.001 








Bold results are significant (p<0.05) 
 
Estimates of median time differences are from Cox models stratified on the characteristic of interest, adjusting and weighting by all other variables, including 
cohort site, and holding covariates at their mean values 
 
All variables are measured at ART initiation, except for Nadir CD4+ Lymphocyte count 
 
*Adjusted model includes all factors described in the table and cohort site 
 
†Inverse Probability of Selection Weights for Sex, Race, and Risk constructed using all other covariates with the addition of cohort sub-site (to account for 
potential differences in clinical practice between sites) 
 




Table 3-3 a,b.  Cause-specific Hazard Ratios (HR) for and median times to (a.) discontinuation of retention and (b.) death 
before discontinuation, with time-varying median CD4+ lymphocyte count after ART initiation, from unadjusted, adjusted, and 












Median Time*† (Years)  
(95% CI) 
Age (per 10 years) 0.70 (0.69, 0.72) 0.77 (0.75, 0.79)   
Sex      Difference = -1.28 
   Male Ref. Ref. Ref. 6.25 (6.02, 6.44) 
   Female 1.24 (1.17, 1.31) 0.86 (0.81, 0.92) 0.88 (0.83, 0.95) 7.53 (7.00, 8.20)  
Race      Difference = 2.70 
   Non-Black Ref. Ref. Ref. 8.31 (7.94, 8.40) 
   Black 1.12 (1.07, 1.17) 1.21 (1.15, 1.26) 1.21 (1.17, 1.26) 5.61 (5.30, 5.80) 
Risk      Difference = 2.28 
   Non-IDU Ref. Ref. Ref. 7.73 (7.47, 8.29) 
   IDU 1.06 (1.00, 1.11) 1.26 (1.19, 1.34) 1.36 (1.29, 1.43) 5.45 (5.12, 5.88) 
Median CD4+ Lymphocytes‡      
<200 cells/mm3 Ref. Ref.   
200-349 cells/mm3 1.05 (0.98, 1.03) 1.00 (0.93, 1.08)   
350-499 cells/mm3 1.11 (0.97, 2.36) 1.00 (0.92, 1.09)   
≥500 cells/mm3 1.04 (1.13, 1.20) 0.92 (0.84, 1.00)    
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Stratified Log-Rank Test (Score) Unadjusted Adjusted Weighted P-value*† 
Female Sex 55.4 3890 13.3 <.001 
Black Race 25.6 3920 102 <.001 
IDU Risk 3.79 3939 112 <.001 
Bold results are significant (p<0.05) 
 
Estimates of median time differences are from Cox models stratified on the characteristic of interest, adjusting and weighting by all other variables, including 
cohort site, and holding covariates at their mean values 
 
All variables are measured at ART initiation, except for Nadir CD4+ Lymphocyte count 
 
*Adjusted model includes all factors described in the table plus baseline CD4+ lymphocyte count at ART initiation and cohort sub-site 
 
†Inverse Probability of Selection Weights for Sex, Race, and Risk constructed using all other covariates with the addition of baseline CD4+ lymphocyte count at 
ART initiation and cohort sub-site (to account for potential differences in clinical practice between sites) 
 

















Median Time*† (Years)  
(95% CI) 
Age (per 10 years) 1.40 (1.34, 1.46) 1.43 (1.36, 1.51)   
Sex       
   Male Ref. Ref. Ref. >10 Years 
   Female 0.75 (0.64, 0.87) 0.87 (0.74, 1.04) 0.78 (0.65, 0.93)  
Race       
   Non-Black Ref. Ref. Ref. >10 Years 
   Black 1.27 (1.15, 1.41) 1.23 (1.10, 1.37) 1.13 (1.03, 1.23)  
Risk       
   Non-IDU Ref. Ref. Ref. >10 Years 
   IDU 1.27 (1.13, 1.44) 1.18 (1.04, 1.34) 1.35 (1.20, 1.53)  
Median CD4+ Lymphocytes ‡      
<200 cells/mm3 Ref. Ref.   
200-349 cells/mm3 0.38 (0.32, 0.44) 0.38 (0.33, 0.45)   
350-499 cells/mm3 0.23 (0.19, 0.28) 0.25 (0.20, 0.30)   
≥500 cells/mm3 0.18 (0.15, 0.22) 0.20 (0.16, 0.25)   
Stratified Log-Rank Test (Score) Unadjusted Adjusted Weighted P-value*† 
Female Sex 14.5 912 8.08 <.001 
Black Race 21.6 905 6.83 <.001 
IDU Risk 14.8 910 21.9 <.001 
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Bold results are significant (p<0.05) 
 
Estimates of median time differences are from Cox models stratified on the characteristic of interest, adjusting and weighting by all other variables, including 
cohort site, and holding covariates at their mean values 
 
All variables are measured at ART initiation, except for Nadir CD4+ Lymphocyte count 
 
*Adjusted model includes all factors described in the table plus baseline CD4+ lymphocyte count at ART initiation and cohort sub-site 
 
†Inverse Probability of Selection Weights for Sex, Race, and Risk constructed using all other covariates with the addition of baseline CD4+ lymphocyte count at 
ART initiation and cohort sub-site (to account for potential differences in clinical practice between sites) 
 
















Figure 3-3 a,b,c. Violin plots of sample age distributions at ART initiation (years), by 














Assessment of proportional hazards assumption 
 
Cox proportional hazards regression in the context of competing events censored 
for one another assumes a constant cause-specific sub-hazard and, as always the case in 
Cox regression, proportionality of hazards.  This proportionality assumption can be 
assessed by fit of the scaled Schoenfeld residuals to an estimated ratio coeffecient of 1 (or 
a log difference of 0) for the covariate of interest plotted against the event times. (30) The 
plots of these residuals should exhibit a flat horizontal fitted line close to a log value of 0 
to demonstrate no violations of this assumption.  The weighted Schoenfeld residual plots 
for both discontinuation from retention and death by age, sex, and risk when stratifying 
estimates by Black race are presented below (Appendix Figure 3-1).  They demonstrate 
no violations of the proportional hazards assumption. Similar procedures were conducted 






Construction of stabilized inverse probability of selection weights 
Inverse Probability of Selection Weights (IPW) were used in this context to 
eliminate confounding by balancing populations with respect to the exposures of interest 
(sex, race, and HIV risk) conditional on confounders such as baseline age and CD4+ 
lymphocyte count, and to assess the direct effect of these exposures on the event of 
interest by reweighting according to the mediating factor of nadir CD4+ lymphocyte 
count after ART initiation.  In this analysis, the potential confounders of baseline age, 
sex, race/ethnicity, HIV risk factor, and cohort site were used to construct IPW, 
excluding sex, race, or HIV risk from the denominator when using that respective factor 
as the exposure.  These weights were applied to the marginal models and, in robust 
estimation, to the conditional fully adjusted models.  Survival curves were created using 
predictions from both the weighted and adjusted estimates, noting that the stratified 
adjusted curves used covariate values fixed at their means across strata of the exposure of 
interest. (27,29) Because these were time-fixed confounders, single weights across all 
timepoints for an individual were used. The weights were also stabilized and truncated at 
the 5th and 95th percentiles to improve balance (Appendix Figure 3-2).(28) 
The weights were constructed with regression models estimating the probability 
of exposure received, conditioning on potential confounding or mediating factors.  
Because the exposures of interest were binary (sex was male vs. female, race was Black 
vs. non-Black, and risk was IDU vs. non-IDU), a logistic regression model was used to 
create the IPW.  For sex, the regression model for the stabilized weights was specified as: 
IPWi =
Pr(sexi = female)
Pr(sexi = female | agei, racei, riski, Baseline-CD4i,Nadir-CD4i, sitei )
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Similar models were used to construct weights by race and risk.  The truncated weights 
for female sex had a mean value of 0.94 (IQR: 0.85-1.04) and a range of 0.42-1.50. The 
truncated weights for Black race had a mean value of 0.95 (IQR: 0.69-1.06) and a range 
of 0.58-1.81.  The truncated weights for IDU risk had a mean value of 0.96 (IQR: 0.85-
1.09) and a range of 0.57-1.34.  These distributions indicate a lack of extreme values 
which could lead to unstable effect estimates. The untruncated and truncated distribution 
of weights accounting for sex, race, and HIV risk are illustrated below (Appendix Figure 
3-2). 
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Background: Clinical retention is central to the HIV care continuum, a key framework 
for  improving individual- and population-level HIV outcomes. Here, we  describe trends 
in retention across time and geographic regions among participants in a large diverse HIV 
cohort collaboration in the United States.  
Methods: Data from adults in 12 clinical cohorts of the North American AIDS Cohort 
Collaboration on Research and Design (NA-ACCORD) were used to estimate the 
percentage of individuals successfully retained in care by geographic regions of the 
United States between 2000 and 2010.  Individuals were assigned to regions defined by 
the U.S. Centers for Disease Control and Prevention (CDC) based on 3-digit ZIP Code 
Tabulation Area (ZCTA) and state-level residential data (10 cohorts) and clinic location 
as a proxy for residence (2 cohorts). Successful retention among those with ≥1 HIV 
primary care encounter during the study period was defined by the National HIV/AIDS 
Strategy/Institute of Medicine indicator: ≥2 encounters within a calendar year, >90 days 
apart.  Temporal trends and regional differences were analyzed among individuals using 
modified Poisson regression with a Generalized Estimating Equation (GEE) for clustered 
outcomes over time, and among ZCTAs of residence using logistic regression with GEE.  
Individual time in care, age, sex, race/ethnicity, and HIV acquisition risk, and ZCTA-
level median age, proportion of female sex, proportion of Black race, proportion of rural 
residence, and proportion living below the federal poverty line were adjusted for as 
potential confounders of the geographic relationship with retention. 
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Results: Among 78,993 adults with 444,212 person-years of follow-up, the median 
duration of time observed in care was 7 years (Interquartile Range: 4-9 years).  Our 
Midwest study population captured the smallest percentage of regional prevalent HIV 
cases with 3.5% (3,565/100,967) and the West the most with 7.0% (11,695/167,117), 
using 2010 CDC data.  The percentage of individuals successfully retained increased 
from 2000 to 2010 in each region: from 73% (5,000/6,875) to 85% (7,189/8,462) in the 
Northeast, 75% (1,778/2,356) to 87% (1,630/1,880) in the Midwest, 68% (8,451/12,417) 
to 80% (9,892/12,304) in the South, and 68% (5,147/7,520) to 72% (6,401/8,895) in the 
West. In adjusted regression models, there was a trend for improved retention over time 
(p<0.01) across all regions. Additionally, over the study period, the probability of 
retention was lower in the West and South, and higher in the Midwest, compared to the 
Northeast (p<0.01). 
Conclusions: Differences in HIV outcomes (e.g. disease progression, case fatality) have 
been noted between regions of the United States. In our clinically engaged population, 
the percent of patients retained in care improved over time for all regions, with 72-87% 
retained in care in 2010. However, there were significant differences in retention between 
regions even after adjusting for population demographic and risk differences. Further 
analysis incorporating smaller geographic divisions with richer individual- and 
population-level data (e.g., Medicaid availability for the uninsured) will be required to 
better understand how geographic factors impact retention in clinical care and HIV 





The description and analysis of epidemiologic outcomes using geographic or 
spatial patterns has been central to the practice of epidemiology as a modern science 
since John Snow produced his iconic map of a deadly cholera outbreak in 19th-century 
London.(1) Mapping outcomes and identifying geographic determinants of health 
disparities have also provided essential evidence in public health policy decision-making, 
directing funding and interventions to locales of greatest need and most likely positive 
impact.(2-7) The field of HIV epidemiology has been no exception, and analyses of 
geographic variation in determinants of transmission dynamics, intervention 
effectiveness, and the temporal trends, extent, and severity of the disease have yielded 
insights into the changing nature and trajectory of the pandemic.(8-16) In the case of the 
United States (U.S.), HIV prevalence, incidence, disease progression, mortality, and 
treatment characteristics have been noted to differ across geographic regions and states of 
the country.(17-21)  
Retention in care has been shown to be associated with improved access to ART, 
greater likelihood of virologic suppression, and less rapid HIV disease progression.(22-26)  
Similarly, the same demographic, clinical, and socioeconomic factors (e.g., younger age, 
Black race, higher CD4 count, and unstable housing status) have been repeatedly 
associated with suboptimal retention in various contexts, though these analyses have 
focused on geographic heterogeneity in the patient population as a potential source of 
clinical retention differences in either a limited fashion or not at all.(27-38) Further, some of 
the studies in which these patterns of care were discerned may have cohort-specific traits 
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that could limit their external generalizability to persons living with HIV/AIDS 
(PLWHA) in the U.S.  Nevertheless, recent major policy initiatives, including the 
National HIV/AIDS Strategy (NHAS), have identified improving clinical retention as a 
goal central to improving outcomes across the HIV Care Continuum in the U.S.(39-41)   
We therefore sought to describe and quantify the geographic heterogeneity of 
clinical retention between 2000 and 2010 within a large and geographically diverse HIV 




Population and study design 
The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) represents North America as a member of the International epidemiologic 
Databases to Evaluate AIDS (IeDEA) project.  The NA-ACCORD began collecting data 
from multi- and single-site interval and clinical cohorts in 2006.(43) The Institute of 
Medicine of the National Academies (IOM) has designated the NA-ACCORD as one of 
12 data systems appropriate to assess quality of care goals, such as improving clinical 
retention, in the NHAS and Affordable Care Act due to its size and demographic 
similarity with PLWHA in the U.S.(24)  Details of the data collection and submission 
process for the NA-ACCORD have been published previously.(44)   Briefly, clinical, 
demographic, and geographic data from 25 cohorts (including multiple laboratory values 
and collection dates, medical diagnoses and dates, antiretroviral medication names and 
prescription dates, clinic encounter information, basic insurance status, state and 3-digit 
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zip code of residence) are transmitted to a centrally-administered Data Management Core 
semi-annually where all contributed datasets are harmonized. Data undergo quality 
control for completeness and accuracy, including measures to reduce the probability that 
an individual was concurrently participating in more than one clinical cohort. Both 
historic clinic encounter and laboratory collection data were included in the latest round 
of data uploads for 2011 (spanning the period 2000 to 2010). The activities of both the 
NA-ACCORD centrally and each participating cohort have been reviewed and approved 
by their respective local institutional review boards. 
Among clinical cohorts, only patients with ≥ 2 clinic visits within 12 months were 
enrolled into the NA-ACCORD, limiting the NA-ACCORD clinical population to 
patients established “in care” proximal to cohort entry; this is assessed by sites based on 
clinic encounter data.  
Adult participants who had ≥ 1 HIV primary care visit between January 2000 and 
December 2010 were included in this longitudinal, retrospective cohort study. Interval 
cohorts were excluded to allow an exclusive focus on patterns of patient clinical care.  
Canadian cohorts were excluded to allow an assessment of the regional differences in 
clinical retention patterns within the U.S.  The 12 included clinical cohorts were 
comprised of patients from all 50 U.S. states, Washington, D.C., and Puerto Rico, with a 
median number of 75 (interquartile range: 31-116) of 887 US 3-digit ZIP Code 
Tabulation Areas (ZCTA)s represented and 167 clinical sites located in areas of dense 
population across the country (Figure 4-1).  
Retention measures, factors associated with retention, and follow-up 
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The outcome was clinical retention, defined using the IOM indicator: ≥ 2 HIV 
primary care encounters within each calendar year, ≥ 90 days apart. Inpatient visits were 
excluded.  
Participant age (categorized as <40 years, 40-49 years, 50-59 years, and ≥60 years 
of age), sex, race/ethnicity (categorized as White, Black, Hispanic, or other/unknown), 
HIV acquisition risk factor (categorized as male sexual contact with men (MSM), 
injection drug use (IDU), heterosexual contact, or other/unknown), receipt of ART for ≥6 
months in a year (≥3 antiretroviral agents from ≥2 classes, or a triple 
nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) regimen containing abacavir 
or tenofovir), CD4+ cell count, HIV-1 RNA, and geographic location of residence (US 
Centers for Disease Control (CDC)-defined region, state, and ZCTA) were included in 
descriptions and analyses of factors by which clinical retention may have differed.  
ART receipt, CD4+ cell count, and HIV-1 RNA were excluded from regression 
analyses due to their potential to induce bias as time-dependent confounders of the 
relationship between demographic factors and clinical retention as a repeated outcome.  
Geographic location of patient residence was collected at cohort entry and did not vary 
over time. 
Individual data were summarized into one observation per year between the year 
of their entry into the cohort (2000, at the earliest) and the year of their final encounter 
prior to the end of 2010.  The initial year of care in the cohort was excluded if the patient 
entered in the final quarter of a calendar year (and were thus ineligible to be “retained” in 
their year of entry into care).  Year of death during the study period was excluded from 
analyses due to individuals not being uniformly “at risk” for successful retention in the 
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year of their death.  Follow-up time ranged between a minimum of 1 and a maximum of 
11 years, and individuals contributed multiple outcomes over the course of the study.   
Additional geographic information 
 As described above, location of patient residence by ZCTA and state were 
collected by individual clinical cohorts within NA-ACCORD and transmitted to the Data 
Management Core.  Data consistency checks were performed to ensure that ZCTA of 
residence corresponded correctly with state of residence (as ZCTAs may be aggregated to 
the state-level along coterminous boundaries).  State of residence was used to assign 
patients to geographic regions of the U.S. based on CDC and US Census Bureau 
definitions.  US CDC-defined Regions were as follows: Northeast: CT, ME, MA, NH, 
NJ, NY, PA, RI, VT; Midwest: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI; 
South: AL, AR, DE, DC, FL, GA, KY,  LA, MD, MS, NC, OK, SC, TN, TX, VA, WV; 
and West: AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.(45)  
Demographic, geographic, and economic characteristics of ZCTAs were derived from 
2000 and 2010 US decennial census files and assigned as follows: for years 2000-2003, 
data from the 2000 census were used; for years 2008-2010, data from the 2010 census 
were used; for years 2004-2007, the mid-point estimates between census years 2000 and 
2010 were used.  Census-derived variables included the median age within the ZCTA and 
the proportions of the ZCTA that were of female sex, of Black race, residing in a rural 
area, and living below the Federal poverty level. Rural areas were defined by the US 
Census Bureau as all population, housing, or territory not residing in an urban area 
(comprised of ≥ 50,000 individuals) or an urban cluster (comprised of ≥ 2,500 but 
<50,000 individuals). The poverty level defined by the US Census Bureau for an 
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individual in the 48 contiguous US states in 2000 was $8,350 and in 2010 was 
$10,830.(46) 
 For participants from 2 clinical cohorts whose residential data was unavailable, 
clinic location was used as a proxy for state of residence, but not for ZCTA of residence; 
individuals from these cohorts were included in descriptions and analyses of regional and 
state-level differences in retention but not in analyses using ZCTA-level data. For ZCTA-
level analyses, individual characteristics from NA-ACCORD participants were 
aggregated to the ZCTA level as the median age in the sample within the ZCTA, and the 
proportion of the sample within the ZCTA that were of female sex, of Black race, and 
that had IDU as an HIV risk factor. 
 All proportions at the ZCTA level were mean-centered to ease interpretation in 
regression modeling.   
Statistical models and methods 
Regional differences in the percentage of patients clinically retained within strata 
of demographic and clinical characteristics were detected by χ2 test. Modified Poisson 
regression using a Generalized Estimating Equation (GEE) approach was used to assess 
temporal trends and determine the relative risks (RR)s and 95% confidence intervals 
(CI)s of retention based on demographic and geographic factors.(47) An unstructured 
working correlation was used for repeated outcomes within individuals in the GEE 
regression.(48,49) Time during the study period (i.e., study year) was included in models as 
a restricted cubic spline with 3 knots (at 2, 6, and 10 years) and as a categorical term for 
predictive margins.(50) All individual-level models were also adjusted for total time 
contributed to the study by an individual (time-fixed). 
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An alternative mixed effects approach that could be applied would model 
retention changes among individuals nested within ZCTAs, nested within states, nested 
within regions. The regression assumptions and interpretation of individual-level effects 
differs from the population-averaged effects obtained under the GEE regression; as 
population-averaged effects are generally viewed as more germane to policy decisions, 
and there is evidence that mixed effects approaches may lead to the induction of bias in 
this context, the population-averaged model was chosen.(51,52) However, sensitivity 
analyses using mixed effects models with random effects at the ZCTA-, state-, and 
region-levels yielded no inferential differences compared to the GEE model (data not 
shown).  
As a complement to these models, ZCTA-level differences were also explored 
using logistic regression with GEE to model the proportion retained, adjusting for 
individual and ZCTA-level census characteristics, and applying the predictions derived 
therefrom in clustering analyses to detect retention below levels expected based on 
geographic location and time of measurement.(53-55) The Kuldorff scan statistic was used 
to detect non-random variation in the outcome over space and time based on a Poisson 
distribution of counts within each ZCTA where observations were available.  This was 
not a global clustering test (e.g., Moran’s I, which tests for any non-random geographic 
variation in the outcome) but an algorithm that directly identified locations that may be 
clusters by likelihood ratio testing of overlapping space-time cylinders (volumes which 
deviate from an assumption of random geographic variation at that specific location over 
time).(55) Standard Monte Carlo hypothesis testing using 999 random replicates was used 
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to detect significant deviations from a null hypothesis of no non-random geographic 
variation in the outcome at a specific location and time.(56) 
Additional details of Poisson and logistic regression models with GEE at the 
individual and ZCTA levels, respectively, including a comparison of models 
incorporating alternate terms for study time, descriptive maps, and supplemental tables 
and plots, are available in the Appendix. Maps were generated using ArcGIS version 10.1 
(Environmental Systems Research Institute, Redlands, CA), statistical analyses were 
performed using Stata version 12.1 (StataCorp, College Station, TX), and cluster 




Among 78,993 adults with 444,212 person-years of follow-up, the median time in 
care was 7 years (Interquartile Range: 4-9 years). There were significant differences 
between US geographic regions in the percentage of participants retained within strata of 
every individual-level characteristic included in our study (Table 4-1).  Our Midwest 
study population captured the smallest percentage of regional prevalent HIV cases with 
3.7% (3,583/97,019) and the West the most with 7.5% (12,037/161,308), using CDC data 
from 2009 (the last year in which all 12 clinical cohorts contributed data).(45)  The 
percentage of individuals successfully retained increased from 2000 to 2010 in each 
region: from 73% (5,000/6,875) to 85% (7,189/8,462) in the Northeast, 75% 
(1,778/2,356) to 87% (1,630/1,880) in the Midwest, 68% (8,451/12,417) to 80% 
(9,892/12,304) in the South, and 68% (5,147/7,520) to 72% (6,401/8,895) in the West 
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(Figure 4-2). In adjusted regression models including the interaction of region by time, 
there was a trend for improved retention over time (p<0.01) across all regions. 
Additionally, over the study period, the probability of retention was lower in the West 
(Risk Ratio (RR): 0.89; 95% Confidence Interval (CI): 0.88-0.91) and South (RR: 0.95; 
95% CI: 0.94-0.96), and higher in the Midwest (RR: 1.02; 95% CI: 1.00-1.05), compared 
to the Northeast (p<0.01).  Other factors such as younger age, Black race, and IDU as 
HIV risk factor were also significantly associated with a decreased likelihood of retention 
(Figure 4-3).  Models testing for a race-by-region interaction showed no significant effect 
modification for racial differences in retention by region (data not shown).  In addition, 
though state-level patterns generally conformed to the regional patterns observed 
(Southern and Western states lag in observed and predicted retention probabilities over 
time), adjusting for state in the full model did not improve the model fit considerably. 
(Appendix Figure 4-1f). 
The predictive margins (i.e., the marginal probability of the outcome if every 
individual in the model were assigned the selected characteristic) interacting with time 
showed similar patterns of increasing probability of retention over time while differences 
across age, sex, race/ethnicity, and HIV risk categories persisted (p<0.01 for every 
category-by-time interaction) (Figure 4-4).(57)  
In logistic regression models for the proportion retained at the ZCTA level over 
the study period, only an increase in the NA-ACCORD sample’s aggregate median age 
(Odds Ratio (OR): 1.10 per year; 95% CI: 1.09-1.11) and a decrease in the census-based 
mean-centered proportion of a ZCTA that were of Black race (OR: 0.36 per percentage 
difference increase from the mean proportion; 95% CI: 0.15-0.87) were significantly 
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associated with improved retention (Table 4-2).  Clustering analyses identified 7 isolated 
ZCTAs with lower than expected retention (comparing observed to predicted proportions 
from the fully adjusted ZCTA-level logistic regression model), with 5 of the 7 ZCTAs 




Because geographic, racial, and socioeconomic disparities in the US HIV 
epidemic have been noted, it is logical to explore whether the demographic, economic, 
and risk behavior differences in populations residing in different parts of the country fully 
explains the apparent geographic variation in HIV care and outcomes.(9,20,21) Retention in 
clinical care for HIV-positive individuals remains vitally important to advancing the 
treatment of HIV within individuals and to promoting the prevention of HIV at the 
population level through improved access to antiretroviral therapy and virologic 
suppression- downstream stages in the continuum of care.(25) Yet engagement and 
retention in care require consistent and ongoing interaction with the healthcare system, a 
process which may include various obstacles which differ geographically (due to 
economic, political, cultural, or other factors).(34,58) In consideration of these issues, our 
aim in describing the geography of clinical care experiences in a large proportion of US 
PLWHA over a recent and long time period was to provide evidence for evaluating 
benchmarks of national HIV policy goals and advancing the understanding of factors 
pertinent to public health interventions.(41)  
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In our clinically engaged population, the percent of patients retained in care 
improved over time for all regions, with 72-87% retained in care in 2010. The 
improvement of clinical retention levels over time across all US regions confirms the 
work of this and other groups, and may provide public health practitioners and clinicians 
with a note of cautious optimism.(38,42) Even after adjusting for demographic, geographic, 
and risk factor differences, and after accounting for differential contributions of time at 
risk for leaving care, the significant upward trend persists.   
However, the same groups that are consistently identified as having increased 
risks for suboptimal clinical retention, and inferior HIV outcomes in general, emerge 
again in this analysis as lagging behind in the pursuit of a care continuum without 
“leaks”: younger individuals, Black patients, and those with IDU as HIV risk 
factor.(28,31,59-61) Even though the unadjusted retention rates among these groups 
approaches the NHAS goal of 80% (among Ryan White clients), there is room for 
improvement when compared to their HIV-infected peers.  Given those deficits, and the 
fact that risk networks, culture, and socioeconomics may differ radically across regions, 
states, and more granular geographic levels of the country, the identification of locales 
that may benefit most from interventions to improve healthcare quality, access, and 
retention remains as important as ever.  The monitoring of geographic trends in HIV 
clinical care, including all stages of the continuum, is therefore a reasonable and 
important activity to provide evidence for targeted outreach beyond a simple risk-group 
basis.   
The additional analysis of ZCTA-level data using clustering data illustrates the 
power of these methods to identify specific jurisdictions of concern for lagging progress 
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in continuum of care outcomes.  Though the clustering analyses exhibited a different 
pattern of areas with suboptimal retention compared to the differences evident across 
larger geographic divisions (i.e., ZCTAs located primarily in the Northeast vs. the 
Southern and Western regions and states), their value lies in the additional layers of 
evidence they may provide to policy makers, particularly if individual-level data is 
unavailable.  Population-level differences may also be a desirable focus for policy 
purposes, and when considering aggregate characteristics separately from individual 
characteristics related to care, these analyses may or may not yield consistent inferences 
with individual-level analyses. In this case, the differences are unlikely to stem from 
confounding by measured factors since the clustering analyses were adjusted using 
individual-level data, though they may be confounded by characteristics of the area of 
aggregation that were unavailable. These differences may derive from the variable ability 
of cluster detection to identify outlying populations relative to populations at risk under 
different levels of aggregation (e.g., comparing ZCTAs to states to regions).(62)  The 
difference in inferences across population levels may also be related to the limits for 
comparing divisions to one another based on the total population at risk at any single 
timepoint.  For example, it is plausible that, though the South has lower retention rates 
compared to other regions, because this region itself contains close to 45% of the study 
population at risk for suboptimal retention, the limit on cluster windows will be reached 
for most geographic divisions (here, ZCTAs) within the South, and they will therefore 
not be compared directly with many geographic divisions within other regions.(56)  In the 
case that outcomes are uniformly poor across a large region, then, one may not expect to 
see as many outlying divisions within that region, relative to other divisions within the 
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same region.  If one were to conduct region-specific cluster detection analyses (limiting 
the ZCTAs under evaluation to a single region for a given analysis), the patterns that 
emerge may be quite different, though this would be answering a different epidemiologic 
question in which the population at risk would not be similar.  Despite the inferential 
limits in this context, with cautious interpretation, these algorithms that evaluate 
systematic differences between neighbors and between earlier and subsequent timepoints 
in the same area offer valuable insight into population-level processes that may be 
occurring in the care continuum at divisions smaller than the state level. 
There were limitations in this analysis due to characteristics of the population 
under study and the unavailability of patient and geographic characteristics relevant to the 
interaction of HIV-positive individuals with the healthcare system.  First, medical 
insurance status and economic security are important proximal factors influencing access 
to and retention in clinical care that we did not have access to.  We did, however, use 
census-derived proxies for socioeconomic data such as the proportion of the ZCTA that 
was rural (which implies longer distances traveled to receive care) and the proportion of 
the ZCTA living below the Federal poverty line (an indication of the resources available 
to patients).  Second, the group under observation was successfully engaged at cohort 
enrollment, and therefore they may not represent populations of great concern in the 
continuum of care (those that are not diagnosed and/or successfully linked to care).  The 
improvement of care quality through the continuum, though, does require monitoring the 
very type of population included in our analyses, and the NA-ACCORD has been 
endorsed as one of 12 data systems appropriate to monitor progress in improving patient 
participation in the continuum of care.(24) Third, we did not adjust or stratify our retention 
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predictions and geographic analyses according to immune health status (CD4+ 
lymphocyte count or HIV-1 RNA viral load).  This was due to the fact that we analyzed 
individuals longitudinally, and the repeated outcomes (retention status) were both 
influenced by immune status at prior time-points and influenced future immune status.  
Analyzing this structure of time-dependent mediation with a recurring outcome that 
confounds the mediation pathway at future time-points was not possible with the methods 
we employed here, but we intend to address these questions in the near future. Finally, 
scrutinizing outcomes at varying levels of geographic resolution is quite useful (and 
perhaps necessary) for detecting patterns that may otherwise be obscured.(62)  Noting 
patterns across the ZCTA, state, and region level, our work found fairly consistent trends, 
though the quality of the inferences may not necessarily reflect the level at which public 
health actions are likely to be taken and at which effects may be most powerfully felt 
(Figure 4-6). Further analysis incorporating smaller geographic divisions with richer 
individual- and population-level data (e.g., Medicaid status at the individual-level, and 
percentage of population without insurance eligible for Medicaid coverage at the state-
level) will be required to better understand how geographic factors impact retention in 
clinical care and HIV outcomes.   
Using the remarkable breadth and depth of data available through North 
America’s largest collaborative HIV cohort, our analysis demonstrated a persistent 
upward trend in clinical retention across the U.S., but one that was differential in its 
extent by region. This corresponds with observations of regional differences in other HIV 
outcomes and highlights the utility of geographic data and analyses in monitoring 
progress in the continuum of care on both a national and a local basis. There are policy 
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prescriptions and public health actions that may help stem the tide of the epidemic, but 
knowing where and when to apply them is surely a critical piece of information. 
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Table 4-1. Percent of person-years successfully retained (with % person-years 
contributed) in the NA-ACCORD, defined by encounters, stratified by demographic, 




(% PY ctrbtd.) 
Northeast 
% PY Retained 
(% PY ctrbtd.) 
Midwest 
% PY Retained 
(% PY ctrbtd.) 
South 
% PY Retained 
(% PY ctrbtd.) 
West 
% PY Retained 
(% PY ctrbtd.) 
Total 7    444,212 (100) 78 (22) 81 (7) 73 (45) 75 (26) 
Age (years)*       
≤39 118,626 (27) 69 (24) 72 (24) 63 (28) 62 (27) 
40-49 166,389 (37) 77 (38) 81 (37) 73 (36) 70 (39) 
50-59 114,784 (26) 83 (28) 84 (27) 80 (26) 76 (24) 
≥60 44,413 (10) 88 (10) 89 (12) 88 (10) 83 (10) 
Sex       
Male 367,048 (83) 78 (74) 80 (86) 74 (82) 71 (90) 
Female 77,164 (17) 77 (26) 83 (14) 69 (18) 67 (10) 
Race/Ethnicity       
Non-Hisp. White 183,580 (41) 80 (28) 83 (45) 77 (36) 71 (62) 
Non-Hisp. Black 194,787 (44) 77 (51) 78 (46) 71 (55) 68 (18) 
Hispanic 48,125 (11) 78 (19) 84 (4) 73 (7) 71 (12) 
Other/Unk. 17,720 (4) 70 (2) 81 (5) 72 (2) 67 (8) 
HIV Risk Factor        
MSM 152,691 (34) 79 (28) 83 (30) 73 (28) 69 (52) 
IDU 86,301 (19) 76 (26) 76 (18) 72 (20) 69 (14) 
Hetero 95,869 (22) 78 (30) 82 (17) 68 (23) 66 (13) 
Other/Unk. 109,351 (25) 78 (16) 81 (35) 79 (29) 77 (21) 
CD4+ Cell Count (cells/mm3)a     
<200 73,559 (17) 81 (16) 85 (15) 74 (18) 76 (15) 
200-349 75,340 (17) 84 (18) 87 (15) 79 (17) 74 (17) 
350-499 77,588 (17) 85 (17) 89 (16) 81 (17) 74 (19) 
≥500 134,202 (30) 86 (30) 90 (31) 82 (28) 74 (33) 
Missing 83,523 (19) 49 (19) 56 (23) 50 (20) 47 (16) 
HIV-1 RNA (copies/mL)b     
≥200 copies 178,803 (40) 76 (41) 81 (38) 70 (44) 68 (34) 
<200 copies 198,980 (45) 88 (47) 92 (42) 86 (39) 77 (54) 
Missing 66,429 (15) 46 (12) 56 (20) 54 (17) 46 (13) 
ART Receipt (≥6 months/year)     
No ART 170,251 (38) 59 (37) 62 (37) 55 (41) 53 (35) 







Percent of person-years retained during the study by encounter (i.e., years “in care” between cohort entry 
and final encounter) is different by region within every stratum (χ2 test, p<0.01) 
a: at the first measurement in each calendar year during follow-up; b: at the last measurement in each 
calendar year during follow-up 
Region information missing for residents of Puerto Rico (N=255), the US Virgin Islands (5), or where 
state-level residence was missing (N=12) 
MSM: male sexual contact with men; IDU: injection drug use; Hetero: heterosexual contact; ART: 
antiretroviral therapy (≥3 agents from ≥2 classes or a triple-NRTI regimen containing abacavir or tenofovir) 
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Figure 4-1. Geographic distribution of NA-ACCORD clinical cohort sites contributing data to this analysis; map represents the 




Figure 4-2. Temporal trends in percentage of individuals successfully clinically retained in the NA-ACCORD by CDC-defined 
region of the United States, from 2000-2010, overlayed on map representing percentage of prevalent HIV cases captured within the 
































Diamonds are National HIV/AIDS Strategy/Institute of Medicine retention indicator percentages (≥2 visits in a calendar year, >90 days apart).  
 
Squares are Department of Health and Human Services retention indicator percentages (≥1 visit in every semester of a 2-year period, >60 days apart).  
 
Circles are Predictive Margins for the Probability of Being Retained by IOM indicator using a Region-by-Time interaction effect (Fully Adjusted Logistic Model 
with GEE) 
 
U.S. Centers for Disease Control and Prevention (CDC)-defined Regions: 
Northeast: CT, ME, MA, NH, NJ, NY, PA, RI, VT;  
Midwest: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI;  
South: AL, AR, DE, DC, FL, GA, KY,  LA, MD, MS, NC, OK, SC, TN, TX, VA, WV;  




Figure 4-3. Risk Ratio estimates and 95% Confidence Intervals for factors associated with retention, from modified Poisson 






Table 4-2. Estimated 95%Odds RatiosCIs from ZCTA-level logistic regression models 
using GEE with an unstructured working correlation structure, including adjusted 
QIC as a measure of model fit (compared with an independent working correlation 
structure). QIC is the Quasi-likelihood Information Criterion of Pan. 
 
Full Model         Model 2        Model 3 Model 4 
QIC (Adjusted)           8724.7 8724.7 8722.8 8722.3 
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Female Sex 0.74






    
Mean-centered 
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Bold point estimates are statistically significant (p<0.05) 
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Figure 4-5. Cluster analysis of ZCTAs with lower than expected proportions of clinically retained patients, comparing observed 
to predicted counts from fully adjusted logistic regression models with GEE at the ZCTA-level by Kuldorff’s spatial scan statistic 
applied over the period 2000 to 2010. 
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Figure 4-6 a,b,c. (a.) Region-level, (b.) State-level, and (c.) ZCTA-level maps of observed clinical retention status within the 





































































Appendix Table 4-1. Comparison of 95%Risk RatiosCIs from individual-level Poisson 
regression models using GEE with unstructured working correlation structure and 





Including a linear 
term for time 
Including a categorical 
term for time 
Including 
restricted cubic 
spline with 3 
knots for time 
QIC (Adjusted) 852511.1 852029.5 851576.6 852024.1 
Age (years)*             
   ≤39 Reference Reference        Reference Reference 




































Sex             
   Male Reference Reference       Reference Reference 
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Reference Reference       Reference Reference 
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   Time-South 1.02
 1.02 1.02
          
   Time-West 1.00
 1.00 1.01
          
Total Time in 


















Details of the Kuldorff spatial scan statistic and analysis of outcome clustering  
Spatial cluster detection methods were used to analyze non-random geographic 
variation in the proportion of patients clinically retained in each calendar year of the 
study at every ZCTA that contained contributed patient data. Specifically, Kulldorff’s 
spatial scan statistic was used to identify clusters assuming a null distribution of cases 
according to a discrete Poisson point process:  
If 𝐶!   are the random variables (denoting 𝐶 events in area i=1,…,I ) with 
𝐸 𝐶! = 𝜆𝑛! , where 𝜆 is the baseline rate of the event.  That means that the expected 
number of events in an area is the number at risk in that area multiplied by the baseline 
rate.  If the total number of observed cases across all regions is denoted 𝑐! = 𝑐!!!!! , 






) where 𝑛! = 𝑛!!!!!  is the total number of people 
at risk for the event across all areas.  Kulldorff’s spatial scan statistic is then defined by 
circular zones centered in each area, and increasing in radius successively until 50% of 
the at-risk population is covered.  The collection of areas within the zone, z, is considered 
as a potential cluster, and the presence of more (or fewer) cases than expected within the 
zone (based on the baseline rate and the population at risk) fulfills the alternate 







1 𝑐! > 𝜆𝑛! , where 1 𝑐! > 𝜆𝑛!   is an indicator 
function valued at 1 when the number of events is greater than the number expected 
under the null hypothesis, and at 0 otherwise.(55) Statistical inference of the scan statistic 
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can only be determined through Monte Carlo simulation.  This approach was applied 




Appendix Figure 4-2 a,b,c. Comparison of observed with predicted retention 
probabilities from ZCTA-level logistic regression model fit using GEE and adjusting 
for total person-time accrued within the ZCTA, sample-aggregated median age, 
proportion with female sex, proportion of Black race, and proportion with IDU HIV risk 
factor, and census-derived median age, proportion with female sex, proportion of Black 
race, proportion that is a rural area, and proportion living below the Federal poverty line.  
Plots are (a.) Quantile-Quantile, (b.) Normal-Quantile, and (c.) Normal-Probability plots. 
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Summary of key findings 
 
In this dissertation, we examined the epidemiology of clinical retention among HIV-
infected adults in North America, including the magnitude of potential retention outcome 
misclassification, disparities in times to discontinuity of care after ART initiation, and 
geographic differences in clinical retention.  Using data from the North American AIDS 
Cohort Collaboration on Research and Design (NA-ACCORD), a large demographically 
and geographically diverse HIV cohort collaboration in North America with a 
longitudinally-followed clinical population, we identified non-negligible measurement 
error when using laboratory proxies for clinical encounters and observed persistent 
individual- and population-level differences in retention outcomes by age, sex, race, HIV 
acquisition risk factor, and geographic location, despite observing a general improvement 
in retention over time.  
 
In Chapter Two, we assessed the potential for measurement error when classifying 
retention using laboratory measurement dates as proxies for clinical encounter dates, a 
common practice in large cross-sectional and national surveillance studies related to the 
HIV continuum of care.  The rates of retention judged by both metrics improved over the 
study period (70% to 80% by encounters and 66% to 77% by laboratory proxies, from 
2000 to 2010) and agreed fairly well with each other (percent agreement between 78 and 
85%).  After accounting for differences in clinical practice across contributing clinical 
sites, demographic characteristics, and in HIV acquisition risk factors, and using methods 
appropriate for within-individual correlation of retention (whether defined by laboratory 
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proxy or directly by encounter), the nearly 20% percent discordance between measures 
over a decade of observation was modest but significant enough to impact estimates used 
to measure progress toward policy-related benchmarks.       
 
In Chapter Three, we evaluated demographic and HIV acquisition risk factor disparities 
in disruptions of clinical retention after initiation of ART.  By restricting analyses to the 
population successfully linked to care, engaged in care, and initiating therapy, we 
mitigated the influence of potential differences in healthcare access on observed 
differences in retention by sex, race, and injection drug use as HIV risk factor (IDU).  
Analyzing those who started ART between 2000 and 2006 to ensure at least 4 years of 
potential follow-up over the study period (2000 to 2010), the cumulative incidence of loss 
from retention (at least once) over 10 years of follow-up was high, at nearly 74%.  We 
observed significant differences in loss of retention, with men, Black individuals, and 
IDU patients discontinuing earlier after initiating ART, though these differences were 
only made manifest after adjusting for the differing age structures of these populations. 
We also found that males and IDU patients died earlier than females and non-IDU 
patients while successfully retained, even after adjusting for the nadir CD4 count after 
ART initiation as a mediator between demographic or risk factor exposures and retention 
outcomes.  
 
In Chapter Four, we described the geographic distribution of retention across the U.S. and 
analyzed individual- and 3-digit ZIP Code Tabulation Area (ZCTA)-level data to assess 
regional differences and clustering of retention outcomes.  Individuals residing in the 
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South and West were significantly less likely to be retained over the study period (2000 
to 2010) compared to those residing in the Northeast or Midwest, even after adjusting for 
age, sex, race/ethnicity, and HIV acquisition risk differences.  Analyses at the ZCTA-
level revealed the persistent effects of age and race on retention, with a ZCTA’s predicted 
odds of retention decreasing with younger mean patient age within the ZCTA and higher 
proportion of the ZCTA general population being of Black race.  Spatial clustering 
analyses at the ZCTA-level, however, revealed a different pattern, with 5 ZCTAs in the 
Northeast, 1 in the South, and 1 in the West emerging as clusters of suboptimal retention.  
States ranked by median predicted probability of retention over the study period revealed 
patterns similar to those between regions with Southern and Western states faring worse 
in predicted retention compared to Northeast and Midwestern states.   
 
Public health importance 
 
This dissertation directly addresses goals for improved clinical retention among HIV-
infected individuals as outlined in the National HIV/AIDS Strategy (NHAS) and recently 
highlighted in a Presidential Executive Order establishing the “HIV Care Continuum 
Initiative.”(1-3)  Retention in clinical care and patient “churn” (movement through care 
over time) and their impact on the epidemiology, treatment, and prevention of HIV/AIDS 
in the United States and Canada have been described previously.(4,5) By building on this 
work and addressing sources of error in large clinical retention surveillance studies and 
persistent demographic and regional disparities in retention, we may not only alert policy 
makers, public health officials, and epidemiologists to these issues, but we may also 
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equip them with the evidence they need to pursue more focused strategies to improve 
retention and HIV outcomes.(6) 
For retention surveillance estimates lacking longitudinal encounter or “visit” data, 
we may also inform methods such as regression calibration to correct for outcome 
misclassification in the very studies whose results are critical for policy priority setting 
and progress assessment in the NHAS.  The US Centers for Disease Control and 
Prevention (CDC), for example, routinely utilizes mandatorily reported laboratory 
measures to assess clinical retention across jurisdictions and notes this as a limitation in 
estimating prevalent retention.(7,8) Because our work provides an estimate of the 
magnitude of the error involved in their estimates, epidemiologists may be better 
equipped to adjust them or provide upper and lower bounds on their estimates of 
retention.  Providing better evidence to policy makers on whether benchmarks in the 
NHAS are being met may lead to the marshaling of resources toward those areas that are 
still in greatest need.  In addition, more accurate retention estimates may enable more 
accurate estimation of program effectiveness for retention-focused interventions when 
clinic encounter data is unavailable. 
With respect to the sex, race, and risk, differences in retention analyzed in this 
dissertation, the ongoing evaluation of disparities and the tracking of progress in 
narrowing them is essential to assessing the effect of public policy, public health 
programs, and changes in clinical practice over time.(9,10) Race and sex are not risk factors 
that may be intervened on or modified, but noting disparities after accounting for other 
characteristics provides evidence for shifting policy, funding, and intervention priorities.  
In addition, observing the “direct effect” of race or sex on retention, accounting for 
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mediation by disease status (here, nadir CD4 count after ART initiation), is a more 
powerful method for detecting disparities that may be due to factors outside of clinical 
care, such as distal contextual factors.(11-15) 
 Similarly, noting geographic differences in retention outcomes while accounting 
for individual- and population-level characteristics that may influence healthcare 
utilization patterns directs public and political attention toward health disparities that may 
be experienced across a spectrum of diseases, not just HIV disease or healthcare 
access.(16) Our work capitalized on the great geographic diversity of the NA-ACCORD 
population in clinical care to provide a unique perspective on national HIV care 
continuum outcomes that federal health policy advisors and research funding agencies 
may have great interest in. The policies, both social and economic, that differ between the 
same regions that exhibit retention differences should be examined carefully to determine 
what, if any, patterns emerge and which policies may be most harmful or most beneficial.  
The natural starting point for such work is to identify those jurisdictions, whether small 
or large, which are “good” or “bad” actors.  This sort of information can only be derived 
from rich data sources with longitudinal clinical data available for a large and 
geographically dispersed population, such as in the NA-ACCORD.(17) Given the renewed 
focus at the national and state levels on healthcare utilization outcomes as US healthcare 
systems undergo massive changes, analyses of retention “stage” outcomes in the HIV 
care continuum across regions dovetail nicely with national health policy priorities.(2)  
Since improving clinical retention is now widely acknowledged to be a key 
component of patient progression through the HIV care continuum, with the potential to 
reduce HIV incidence through improved virologic control and a “Test and Treat” 
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paradigm, it is also clear that monitoring key populations in which we seek to maximize 
public health impact and highlighting suboptimal outcomes in groups of special concern 
are still necessary steps in an iterative process that strengthens our abilities to meet 
strategic goals. Characteristics associated with negative HIV disease outcomes are also 
associated with suboptimal clinical retention (e.g., minority race, younger age, male sex, 
and history of substance abuse),(18-20) and poor clinical retention has been shown to be 
accompanied by more rapid disease progression and lack of HIV virologic 
suppression.(21,22) Hence, addressing inequitable healthcare access and suboptimal 
retention in such high-risk subpopulations may elucidate the factors that continue to 
cause HIV outcome disparities.(23)  Further, evidence regarding these factors may provide 
local, state, and national policy makers with a framework for eliminating disparities and 
reduce HIV transmission through increased public engagement and resource allocation.   
When the results contained in this dissertation are disseminated to a receptive and 
knowledgeable audience that is ready to act, the identification of intervention targets 
(conceptually and spatially) and barriers to accurate surveillance will be powerful tools, 
perhaps capable of guiding decision-making, resource allocation, surveillance protocols, 
and improved implementation of already formulated “test and treat” strategies. While the 
aims of rapid HIV diagnosis and linkage to care remain crucial, engagement and retention 
in continuous care are essential if these strategies are to accomplish their stated goal of 
halting the spread of this epidemic.(24,25) 
 
Generalizability of results 
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In 2012, the Institute of Medicine of the National Academies (IOM) produced a 
comprehensive report on recommended indicators and data systems for monitoring 
outcomes in the HIV care continuum.  In the report, the IOM endorsed the NA-ACCORD 
as an ideal observational study within which longitudinal analyses of their recommended 
continuum of care indicators could be assessed in a large population of HIV-infected 
adults that is demographically similar to the population of persons living with HIV/AIDS 
(PLWHA) in the United States.(26,27)  The recognition of the power of the NA-ACCORD 
to address questions just such as those posed and answered in this dissertation by an 
august body such as the IOM is encouraging. Though external validity is not an easily 
testable epidemiologic construct, the application of internally valid results to target 
populations at either the present or future times is surely on more solid footing due to fair 
representation and substantial capture (between 3 and 7% in recent years) of HIV-
infected adults in the United States within the study populations of Aims 1 and 3, and of 
HIV-infected adults initiating ART between 2000 and 2006 in Aim 2.    
 In Aims 1 and 3, the study populations were comprised of individuals receiving 
care at clinical cohorts in the NA-ACCORD and with ≥1 encounter between 2000 and 
2010.  The only additional restrictions in Aim 3 were relatively generous, by area of 
residence outside of the four US Census Bureau-defined regions (Northeast, Midwest, 
South, and West).  In both Aims, nearly 80,000 individuals contributed more than 
400,000 person-years in follow-up over a decade.  The demographic composition in both 
of these populations closely mirrors the composition of the cohort as a whole, and 
therefore retains the strength of representativeness, though these are individuals who have 
been successfully linked to care. 
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 In Aim 2, the target population was more narrowly defined as those successfully 
linked to HIV care with access to ART, and therefore the study population inclusion 
criteria were more restrictive.  Ensuring the inclusion of only individuals who were ART-
naïve at the time they initiated ART during the study, and those who had at least 1 year in 
care following the year in which they initiated ART meant a drastic narrowing of the 
cohort population in clinical care.  Even so, the participants in Aim 2 analyses of 
discontinuation of retention after ART initiation numbered more than 17,000 and they 
resided in all 50 US States and 9 Canadian provinces.   
That being said, the clinical population receiving care between 2000 and 2010 and 
eligible for inclusion in these analyses were almost certainly a more robust group with 
greater access to healthcare and HIV services than the groups at highest risk for 
accelerated disease progression and arguably those who may have benefited most from 
improved access to and successful retention in care.(28) The study population, by dint of 
their inclusion in the NA-ACCORD, had attended ≥2 clinic visits within some 12-month 
period before cohort enrollment commenced, and were therefore at least successfully 
linked to care.  The high-risk groups of individuals either not diagnosed, or else 
diagnosed but not linked to care, may not only benefit personally, but because they may 
in fact be drivers of transmission early in their disease, they could be high-reward targets 
of prevention efforts; by engaging them in care and providing them with therapy, a 
disproportionate number of new infections may be prevented.(29)  The results of this work 
may not be applied as readily in these populations because the environmental, economic, 
social, cultural, and other contextual factors most relevant to their engagement and 
retention in healthcare may be very different from what has been measured among the 
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NA-ACCORD clinical population because these groups are likely underrepresented 
within the cohort. 
 Other source populations such as the CDC’s Medical Monitoring Project may 
employ probabilistic sampling methods to achieve greater demographic 
representativeness of PLWHA (at least, of the HIV diagnosed population), and therefore 
may give rise to more representative study populations, but they do not have the 
longitudinal clinical data nor the geographic diversity that the NA-ACCORD 
possesses.(30)  The fact remains, then, that there may be no sources of longitudinal clinical 
data in the North American HIV-infected adult population with quite the same magnitude 
and geographic breadth as the NA-ACCORD.  Therefore, studies such as this, conducted 
in this population, may be the most practically reflective of our desired target population: 
HIV-infected adults with access to clinical care who are at risk of discontinuing clinical 
care after engagement. 
 
Other strengths and limitations 
  
There were several limitations in the research presented here.  Chapters Two through 
Four contain detailed discussions of data and methodological strengths and limitations 
particular to their scope, and they will not be re-presented here.  The focus of this section 
will instead be on general limitations in studying these topics with the available data and 
the most practical methods.   
First, the NA-ACCORD does not currently collect detailed socioeconomic, 
psychiatrically managed mental health, or structured epidemiologic substance abuse 
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assessment data elements.  The lack of high quality data from validated instruments or 
proximal sources (i.e., instead of a state Medicaid expansion decision as a proxy for a 
patient’s access to care, collecting data on a patient’s own health insurance status, 
whether public payor or private) on these potentially important confounders, mediators, 
and effect modifiers of the relationship between other patient characteristics and clinical 
retention status may hinder the construction of internally valid inferences.  However, a 
mitigating factor is that injection drug use history as HIV risk factor was available and 
used as either a predictor or adjustment factor in every Aim.   
Second, if patients leave care and are incarcerated before returning to care, their 
out-of-care risk experience (for both retention and HIV disease outcomes), and their 
likelihood of return in subsequent years will by systematically different for obvious 
reasons.(13,31)  If however, there are patient characteristics that are strongly predictive of 
incarceration in the United States (e.g., young age, male sex, and minority race), the 
models that rely on adjustment by these factors should capture much of this difference.  
That is, the total effect of, for example male sex, on retention will still be observed, 
regardless of the unobserved relationship with the mediating factor (imprisonment).  On 
the other hand, analyzing disparities by stratifying analyses on these potential “common 
causes” may really be revealing differences in incarceration rates.  Similarly, if female 
patients are diagnosed during pregnancy, engage in HIV clinical care during, and then 
discontinue after delivery, there will be no way to distinguish the “pregnancy” year from 
the “non-pregnancy” year in such a patient, as the NA-ACCORD does not currently 
collect pregnancy data.  It is therefore possible that measured disparities in sex may really 
capture some disparities by pregnancy status, if pregnancy is indeed strongly predictive 
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of retention followed by discontinuation from care (inducing bias, since only one sex may 
become pregnant).  However, adjusting for the age structure of females vs. males may 
mitigate some of these differences at older ages.  In both of these cases, it would still be 
desirable to assess disparities by these characteristics whether the mediating factors 
leading to loss of retention are incarceration, pregnancy, or neither.  Of course, in these 
cases, the inferences for public health intervention purposes would be eminently more 
useful if the mediating factors were identified, too (targeting all women when only the 
pregnant women need an intervention, or targeting all youth when only juvenile offenders 
should be assisted with care would be an inefficient use of resources).   
Finally, though inverse probability weighting and clustering methods were used 
for Aims 1 and 2, and Aim 3, respectively, they were not “magical wands” which could 
eliminate data or design limitations.  They are powerful tools, and they worked as well as 
can be diagnosed within the study data or by simulation (for clustering analysis), but 
without reliance on external validation or additional data, there were limits to their 
abilities to overcome potential biases and measurement errors (see discussion of potential 
data limitations above); and as is always the case with observational data, the potential 
for unobserved (residual) confounding cannot be completely circumvented with these 
methods.(32-34)  Indeed, there are some structures of time-dependent confounding and/or 
mediation that involve causally complex relationships with the very factors that must be 
used to construct the weights, entangling their estimation with the outcome at multiple 
timepoints.  For example, use of inverse probability weights to adjust for a confounder-
exposure relationship when the outcome at one timepoint confounds or mediates the 
relationship between the exposure and the outcome at a subsequent timepoint (as is the 
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case with a retention outcome and multiple types of exposures such as ART use or CD4 
count) may be untenable.  The interpretation of such weights would be problematic since 
they depend on both the exposure-outcome relationship and on an exposure-confounding 
relationship.  In the case of the analyses in Aim 1, confounders that were time-fixed and 
not open to influence by retention status at subsequent timepoints (e.g., sex, race, baseline 
age) were used with a laboratory-based measure of retention as the “exposure”, and so 
this limitation did not apply. For Aim 2, a time-to-event analysis was conducted with an 
outcome of first discontinuation of retention after ART initiation; because outcomes were 
not repeated, again, this limitation did not apply.  Even though it may have been desirable 
to estimate the influence of certain exposures on changing retention status over time, 
accounting for time-varying mediation by CD4 count or substance abuse, these analyses 
would have been impractically complex, and alternative designs were used to circumvent 
the peculiar causal structures and analytic consequences they might entail.  However, the 
methodologic tail should not wag the epidemiologic dog.  The questions posed in the 
Specific Aims were open to attack using the regression, weighting, and design techniques 
we applied in our conduct of this research, and the inferences derived are as 





This dissertation does not present a final answer to the problems of so-called “leaks” in 
the HIV care continuum, losing patients between HIV infection (in the earliest stage of 
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the continuum) and successful virologic suppression (at the ultimate stage of the 
continuum).  The NHAS has now been supplemented with the “HIV Care Continuum 
Initiative”, with concrete benchmarks for improving outcomes along the continuum and a 
mandate to monitor improvements in these outcomes on a national basis over time.(2,3)  
Because the NA-ACCORD has been endorsed by the IOM as an ideal data source for 
monitoring these indicators, it is our hope that even more important and impactful 
epidemiologic evidence in this arena may yet be borne from this already fruitful cohort 
collaboration. 
There are multiple, complex factors likely influencing these losses, and though our 
work is a worthy contribution to the body of knowledge concerned with outcomes at the 
antepenultimate stage of the continuum (as formulated by Gardener), it likely has more 
immediate and tangible downstream impact (in receipt of ART and suppression of HIV-1 
RNA) than upstream impact.  With that in mind, there may be multiple ways in which we 
might expand this work in addressing gaps and identifying targets and methods for 
improved retention in clinical care to greater depth and hopefully to greater breadth 
across the continuum. 
With regard to Aim 1, epidemiologists should engage in an open dialogue with 
clinicians and policy makers over meaningful definitions of retention, accounting for the 
influence of changing clinical practice guidelines and massive alterations to the 
healthcare infrastructure of the United States.  As the recommended frequency of CD4 
monitoring, for example, is altered among stably treated patients, surveillance for HIV 
care continuum outcomes based on laboratory measures alone (whether their values or 
their frequency) may become problematic.(35,36) Modeling the agreement between 
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laboratory-based measures and encounter-based measures within different strata of 
laboratory values may be appropriate to assess different effects in different patient 
populations.  Though there has been research indicating that visit-based retention helps 
predict virologic suppression or failure independent of immune health, perhaps including 
a more diverse patient population than that under evaluation in prior work would yield 
differing results.(25) 
 With regard to Aims 2 and 3, expanding the focus of this disparities research to 
encompass important behavioral, social, economic, cultural, and other contextual factors 
would provide refinement to the effect estimates and help identify populations most in 
need of structural or local clinical interventions to improve outcomes across the HIV care 
continuum.  Of course, this would entail measuring and collecting variables such as 
median household income, maximum education level attained, stability of housing status, 
ongoing substance abuse, psychiatric care, and others.(11,12,14,37) For some of these, if 
individual-level assessment or measurement is impractical, residential information 
collected at the clinic-level (e.g., census tract of residence) could serve as a powerful 
proxy measure, though of course care would need to be exercised in interpreting the data 
at different levels of granularity.(38,39) Clustering analyses at these more spatially compact 
levels could also provide more targeted identification of areas that would benefit from 
public health interventions. 
Finally, with regard to all of these analyses and future paths for analyzing clinical 
retention outcomes to affect policy and monitor progress in stemming the epidemic, we 
must expand our horizons for tracking patients throughout their interactions with and 
absences from the healthcare system.  As patients move between providers, perhaps 
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within networks and perhaps without, transition from one healthcare system to another, or 
from one geographic location to another, linkage of data systems is necessary to improve 
the longitudinal observation of individuals.  To this end, partnering with state or local 
health department surveillance systems to track whether patients received reportable 
laboratory testing (indicating at least some interaction with the healthcare system) when 
absent from the clinical cohort would be incredibly beneficial.  This would greatly 
mitigate the possibility of misclassification of retention status (if measured by laboratory 
proxy).  Such partnerships between clinical cohorts and public health officials already 
exist in some jurisdictions, and certainly exist fairly commonly for diseases such as 
tuberculosis to enable improved contact tracing and follow-up for mandatory treatment.  
Alternatively, random samples of the “out of care” population within clinical cohorts 
could be selected for intensive tracking and communication efforts to determine a 
representative sampling of true retention and health status among those absent from care.  
Similar efforts have been utilized to great effect in the context of determining trial 
outcomes among participants lost-to-care in resource-limited settings, where even hard 
outcomes such as death may not be subject to complete ascertainment.(40,41)  Finally, 
greater utilization of state Health Information Exchanges to track care patterns 
longitudinally would be the most desirable, though potentially the most distant, future 
effort.(42,43)  Theoretically, the complete medical history of individuals would be traceable 
nation-wide, yielding a negligible, essentially null misclassification rate for engagement 
with or retention within the healthcare system (within the United States, at least). 
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In conclusion, we identified significant disparities in encounter-based retention by lab-
based proxy measures, sex, race, HIV acquisition risk factor, and geographic area of 
residence using data from participants in the largest North American HIV collaborative 
cohort.  Continuing to monitor progress in meeting national policy benchmarks, including 
surveillance of HIV care continuum outcomes, will entail an appeal to novel data sources, 
a continuation and potential expansion of existing cohort resources and data collection 
efforts, careful application of advanced epidemiologic methods, and attention to the 
policy implications and real-world impact of public health and clinical interventions 
deployed in service of improving clinical retention.  Because individual advancement 
through the continuum of care involves the successful navigation of a complex network 
inside and outside of the healthcare system, overcoming personal, financial, social, and 
cultural barriers, we must arm those who would enact evidence-based policy to help our 
fellow man with the compelling, pertinent, and high quality evidence they require.  
Ultimately, we must all work together to reduce individual- and population-level 
disparities in the achievement of improved HIV outcomes, both in treatment and 
prevention.  This remains our clarion call as HIV epidemiologists, and though a long 
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